Prof Andrew Somogyi
Professor
School of Pharmacy and Biomedical Sciences
College of Health
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Andrew Somogyi is a practicing pharmacist, having graduated from the Tasmanian College of Advanced Education in 1972. He undertook a higher degree (Master of Science-1978) and then PhD (1982) at Sydney University, School of Pharmacy. Andrew then undertook postdoctoral research at the Medical Hospital of the University of Bonn in Germany for 2.5 years under the mentorship of Prof Roland Gugler and Prof Michel Eichelbaum. Following a short period in Melbourne at the then Baker Medical Research Institute in Melbourne, he was recruited as a Research Fellow to the Department of Clinical & Experimental Pharmacology at the University of Adelaide in late 1982. In 1992 he was appointed as Senior Lecturer, then promoted to Associate Professor (1994) and Professor in 2002. He was Deputy Head of the Department between 1992 and 2010. Between May 2005 and December 2010, he was Associate Dean (Research) of the Faculty of Health Sciences. In 2010 he was made an Honorary Fellow of the Faculty of Pain Medicine the Australian and New Zealand College of Anaesthetists. Andrew teaches pharmacology in undergraduate medicine, dentistry, nursing and health science programs. He has an active research program centred on elucidating the dispositional mechanisms for altered human drug response in pain therapeutics, cancer and transplantation through pharmacokinetic, metabolism, pharmacodynamic and pharmacogenomic studies. He has translated his research into clinical practice by establishing a Pharmacogenetics Service at the Royal Adelaide Hospital. Pharmacogenomics and personalised healthcare is a theme of his overarching research and public health focus. He provides regular consultancy on the role of pharmacogenomics in adverse drug reactions to clinicians, patients and the legal profession Australia-wide.
RESEARCH PROJECTS AVAILABLE: Clinical Pharmacogenomics Research Group
Research Project 1
Title: The genetics and pharmacokinetics of acute, chronic and postoperative pain therapy with opioids
Project description: More and more people have chronic pain and more undergo surgery which causes acute pain than candevelop into chronic pain. When we give opioids for such pain relief, the doses can vary 10-fold and some get severe side effects. The reasons are mainly due to the patients genetic make-up and we have studied this overt the past decade. New findings show that it is not just their genetic make-up but their epigenetic make up. We have cohorts of patients that we are studying that include those of European ancestry but also Han Chinese, Malay and Indian. We have shown that ethnicity plays a very important role and we want to study this further. We have acute pain patients, cancer patients and patients who having had surgery go on to develop chronic persistent pain. The latter includes a trial of ketamine to attenuate this postsurgical pain. We look at the genetics of the drugs such as morphine and ketamine in terms of their receptors and pharmacokinetics. There are 4 projects, 1 each in : acute pain, chronic cancer pain, perioperative anaesthesia (propofol) and pain, chronic post surgical pain.
Research Project 2
Title: Biomarker determinants of ketamine for treatment -resistant depression
Project description: We are the trial site for biomarker analysis of two large NHMRC funded clinical trials for investigating the efficacy and side effects to ketamine for treatment-resistant depression and suicidality in youth. Upto now the antidepressants that are prescribed work in less than 1 of 4 patients and takes upto 8 weeks to work, which is a poor outcome. Ketamine is a potential new therapy which is very rapid acting within 4 hours. We need to have a better understanding of the dose, why some don’t respond and why some get unacceptable side effects. Our site will investigate this by measuring blood concentrations of ketamine and metabolites and the genetics of the target sites. Over 300 patients are being recruited so you will be part of a large national group of investigators, the outcome of which may mean a new approved therapy for depression.
Research Project 3
Title: Why do Aboriginal Australians and Papua New Guineans respond differently to Europeans when given medicines
Project description: Aboriginal Australians are vulnerable to not responding as well or better to medicines than Europeans because of their genetic make-up or can have life threatening adverse reactions. By knowing more about the genes that are involved we will be in a better position to personalise medicines for Aboriginal Australians. Our current research has identified that we can do a much better job of identifying why some medicines work better, some worse and why some can cause serious toxicity. We are currently working on statin medicines for reducing cholesterol and in chemotherapy for childhood leukaemia. We have a Papua New Guinea project investigating HIV treatment with antiretrovirals (Pharmacokinetics, Pharmacogenetics)which is uncovering some new findings that have major implications in their treatments.These projects would be ideally suited for a person interested in research into disadvantages peoples in Australia and Papua New Guinea.
Projects available for:list as appropriate
Honours / HDR / Masters
Location:
Helen Mayo Building;
Research project start:
Semester 1 and 2
Special requirements:
vaccination required
| Date | Position | Institution name |
|---|---|---|
| 2005 - 2009 | Associate Dean (Research) | University of Adelaide |
| 2002 - ongoing | Professor in Clinical and Experimental Pharmacology | University of Adelaide |
| 1998 - 1998 | Acting Head of Department | University of Adelaide |
| 1994 - ongoing | Associate Professor | University of Adelaide |
| 1992 - 1993 | Acting Head of Department | University of Adelaide |
| 1992 - 2010 | Deputy Head of Department | University of Adelaide |
| 1991 - 1993 | Senior Lecturer | University of Adelaide |
| 1989 - 1991 | Senior Research Officer | University of Adelaide |
| 1987 - 1988 | Visiting Lecturer | University of Adelaide |
| 1986 - 1988 | Florey Research Fellow | Royal Adelaide Hospital |
| 1983 - 1985 | Senior Research Officer (NH&MRC) | University of Adelaide |
| 1983 - ongoing | Honorary Pharmacologist | Royal Adelaide Hospital |
| 1982 - 1982 | Research Associate | University of Adelaide |
| 1981 - 1982 | Senior Research Officer (NH&MRC) | Baker Medical Research Institute and Alfred Hospital |
| 1980 - 1980 | Scientific Officer | University of Bonn |
| 1974 - 1977 | Tutor | Sydney University |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 1975 - 1978 | University of Sydney | Australia | Doctor of Philosophy (Ph.D) |
| 1974 - 1975 | University of Sydney | Australia | Master of Science (M.Sc) |
| 1973 - 1973 | University of Sydney | Australia | Diploma of Hospital Pharmacy |
| 1969 - 1972 | Tasmanian College of Advanced Education/ University of Tasmania | Australia | Certificate of Pharmacy (Ph. C) |
| Date | Title | Institution | Country |
|---|---|---|---|
| 2010 | Fellow Faculty of Pain Medicine | Australian and New Zealand College of Anaesthetists | Australia |
| Year | Citation |
|---|---|
| 2025 | Conyers, R., Stenta, T., Somogyi, A. A., Kirkpatrick, C., Halman, A., Wang, S., . . . Alexander, M. (2025). Phenoconversion of CYP3A4, CYP2C19 and CYP2D6 in Pediatrics, Adolescents and Young Adults With Lymphoma: Rationale and Design of the PEGASUS Study.. Clinical and Translational Science, 18(4), e70209-1-e70209-13. |
| 2025 | Hayes, V., Mills, L., Byron, G., Stubley, C., Black, E., Trevitt, B. T., . . . Lintzeris, N. (2025). Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.. Drug and alcohol dependence reports, 15, 100329. Scopus1 WoS1 |
| 2025 | Chatterton, M. L., Perez, J. K., Thai, T., Faller, J., Loo, C. K., Glozier, N., . . . Mihalopoulos, C. (2025). Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study. Journal of Affective Disorders, 387, 119502-1-119502-10. Scopus1 WoS1 |
| 2025 | Loo, C., Alonzo, A., Barton, D., Berk, M., Chatterton, M. L., Dong, V., . . . Rodgers, A. (2025). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial: Commentary, author response. The British Journal of Psychiatry, 226(5), 317-318. |
| 2025 | Kang, M., Rice, D., Helsby, N., Somogyi, A., Kluger, M., & Chiang, D. (2025). Establishing the patient acceptable symptom state for patient-reported pain outcomes 6 months after breast cancer surgery. Pain Reports, 10(4), e1297. |
| 2025 | Yong, A. S. J., Brennan, S. E., Bratuskins, S., Freeburn, A., Bedi, G., Burke, R., . . . Bell, J. S. (2025). Development of an Australian Clinical Practice Guideline on methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy for Post-traumatic Stress Disorder.. J Affect Disord, 391(119866), 119866. |
| 2025 | Andriguetti, N. B., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2025). Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea. British Journal of Clinical Pharmacology, 91(12), 1-10. |
| 2025 | Gerstman, M. D., Zhang, R. K., Ho, K. M., Kirkpatrick, C. M. J., Riedel, B., & Somogyi, A. A. (2025). Impact of genetic variations on the pharmacokinetics, dose requirements, and clinical effects of propofol: a systematic review. British Journal of Anaesthesia, 135(3), 594-607. Scopus1 |
| 2025 | Mills, N. T., Nikolin, S., Glozier, N., Barton, D., Baune, B. T., Fitzgerald, P. B., . . . Loo, C. K. (2025). Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study. British Journal of Psychiatry, 227(3), 601-607. Scopus1 |
| 2024 | Wong, A. K., Klepstad, P., Somogyi, A. A., Vogrin, S., Rubio, J., Le, B., & Philip, J. (2024). Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects. Journal of Palliative Medicine, 27(11), 1512-1-1521-10. Scopus1 WoS1 Europe PMC1 |
| 2024 | Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., . . . Rodgers, A. (2024). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial - CORRIGENDUM. British Journal of Psychiatry the Journal of Mental Science, 225(2), 349. Scopus1 Europe PMC1 |
| 2024 | Daly, A. K., & Somogyi, A. A. (2024). Pharmacogenomics in 2023: Big studies, big results, big implications, big responsibilities: Editorial. British Journal of Clinical Pharmacology, 91(2), 3 pages. |
| 2024 | Wong, A. K., Vogrin, S., Klepstad, P., Rubio, J., Le, B., Philip, J., & Somogyi, A. A. (2024). Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?. Pharmacogenomics, 25(14-15), 579-586. |
| 2024 | Altree, T. J., Pinczel, A., Toson, B., Loffler, K., Hudson, A., Zeng, J., . . . Eckert, D. (2024). The effects of low-dose morphine on sleep and breathlessness in COPD: A randomized trial. Chest, 167(6), 1-13. |
| 2024 | Martin, D. M., Harvey, A. J., Baune, B., Berk, M., Carter, G. L., Dong, V., . . . Loo, C. K. (2024). Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS). Journal of affective disorders, 352, 163-170. Scopus7 WoS5 Europe PMC6 |
| 2024 | Barratt, D. T., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. A. (2024). Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.. The Pharmacogenomics Journal, 24(3), 18-1-18-8. Scopus1 WoS1 Europe PMC1 |
| 2024 | Robinson, K. M., Eum, S., Desta, Z., Tyndale, R. F., Gaedigk, A., Crist, R. C., . . . Kharasch, E. D. (2024). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.. Clin Pharmacol Ther, 116(4), 932-938. Scopus15 WoS14 Europe PMC12 |
| 2024 | Somogyi, A., & Chesnot, V. (2024). Glass packaging and its contribution to the UN Sustainable Development Goals. INTERNATIONAL JOURNAL OF APPLIED GLASS SCIENCE, 15(4), 8 pages. WoS2 |
| 2024 | Wong, A. K., Klepstad, P., Rubio, J. P., Somogyi, A. A., Vogrin, S., Le, B., & Philip, J. (2024). Opioid Switch Dosing in Chronic Cancer Pain: A Prospective Longitudinal Study. Journal of Palliative Medicine, 27(3), 388-393. Scopus2 WoS2 Europe PMC2 |
| 2024 | Wong, A. K., Vogrin, S., Le, B., Klepstad, P., Rubio, J. P., Somogyi, A. A., & Philip, J. (2024). Background and Breakthrough Opioid Choice May Determine Different Pain Outcomes. Journal of Pain and Symptom Management, 67(3), e259-e261. |
| 2023 | Toner, A. J., Bailey, M. A., Schug, S. A., Phillips, M., Ungerer, J. P., Somogyi, A. A., & Corcoran, T. B. (2023). Serum lidocaine (lignocaine) concentrations during prolonged perioperative infusion in patients undergoing breast cancer surgery: A secondary analysis of a randomised controlled trial.. Anaesth Intensive Care, 51(6), 310057X231194833. |
| 2023 | Schwartz, O. S., Amminger, P., Baune, B. T., Bedi, G., Berk, M., Cotton, S. M., . . . Davey, C. G. (2023). The Study of Ketamine for Youth Depression (SKY-D): study protocol for a randomised controlled trial of low-dose ketamine for young people with major depressive disorder. Trials, 24(1), 686. Scopus1 WoS1 Europe PMC1 |
| 2023 | Gammal, R. S., Pirmohamed, M., Somogyi, A. A., Morris, S. A., Formea, C. M., Elchynski, A. L., . . . Relling, M. V. (2023). Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype.. Clinical pharmacology and therapeutics, 113(5), 973-985. Scopus39 WoS35 Europe PMC37 |
| 2023 | Philip, J., Wong, A., Pasanen, L., Somogyi, A. A., Rubio, J., Klepstad, P., . . . Le, B. (2023). Establishing a Longitudinal Opioid Pharmacogenomic Registry for Cancer Patients: Feasibility and Acceptability.. Journal of Palliative Medicine, 26(3), 411-417. Scopus6 WoS6 Europe PMC3 |
| 2023 | Lewis, G. N., Rice, D. A., Rashid, U., McNair, P. J., Kluger, M. T., & Somogyi, A. A. (2023). Trajectories of pain and function outcomes up to 5 to 8 years following total knee arthroplasty.. The Journal of arthroplasty, 38(8), S0883-5403(23)00128-6. Scopus7 WoS7 Europe PMC7 |
| 2023 | Chiang, D. L. C., Rice, D. A., Helsby, N. A., Somogyi, A. A., & Kluger, M. T. (2023). The incidence, impact and risk factors for moderate to severe persistent pain after breast cancer surgery a prospective cohort study.. Pain medicine (Malden, Mass.), 24(9), 1023-1034. Scopus11 WoS11 Europe PMC9 |
| 2023 | Ferlini Agne, G., May, B. E., Lovett, A., Simon, O., Steel, C., Santos, L., . . . Franklin, S. (2023). Horse Grimace Scale Does Not Detect Pain in Horses with Equine Gastric Ulcer Syndrome. Animals, 13(10), 1623-1-1623-12. Scopus10 WoS9 Europe PMC4 |
| 2023 | Ferlini Agne, G., Somogyi, A. A., Sykes, B., Knych, H., & Franklin, S. (2023). Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.. Biochem Pharmacol, 214, 1-7. Scopus3 WoS3 Europe PMC1 |
| 2023 | Wong, A. K., Somogyi, A. A., Rubio, J., Pham, T. D., Le, B., Klepstad, P., & Philip, J. (2023). Effectiveness of Opioid Switching in Advanced Cancer Pain: A Prospective Observational Cohort Study. Cancers, 15(14), 1-11. Scopus5 WoS5 Europe PMC3 |
| 2023 | Loo, C., Glozier, N., Barton, D., Baune, B., Mills, N., Fitzgerald, P. B., . . . Rodgers, A. (2023). Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial. British Journal of Psychiatry, 223(6), 533-541. Scopus51 WoS49 Europe PMC40 |
| 2023 | Wong, A. K., Klepstad, P., Somogyi, A. A., Vogrin, S., Le, B., Philip, J., & Rubio, J. P. (2023). Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study. Pharmacogenomics, 24(18), 901-913. Scopus2 WoS2 Europe PMC1 |
| 2022 | Wong, A. K., Somogyi, A. A., Rubio, J., & Philip, J. (2022). The Role of Pharmacogenomics in Opioid Prescribing.. Curr Treat Options Oncol, 23(10), 1353-1369. Scopus25 WoS25 Europe PMC15 |
| 2022 | Somogyi, A. A., Musolino, S. T., & Barratt, D. T. (2022). New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 50(1-2), 127-140. Scopus6 WoS6 Europe PMC4 |
| 2022 | Thomas, J. H. L., Lui, L., Abell, A., Tieu, W., Somogyi, A. A., Bajic, J. E., & Hutchinson, M. R. (2022). Toll-Like Receptors change morphine-induced antinociception, tolerance and dependence: studies using male and female TLR and Signalling gene KO mice. Brain, Behavior, and Immunity, 102, 71-85. Scopus17 WoS18 Europe PMC15 |
| 2022 | Kisely, S., Connor, M., Somogyi, A. A., & Siskind, D. (2022). A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.. Aust N Z J Psychiatry, 57(3), 17 pages. Scopus24 WoS25 Europe PMC16 |
| 2022 | Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729. Scopus16 WoS11 Europe PMC9 |
| 2022 | Kluger, M. T., Rice, D. A., Borotkanics, R., Lewis, G. N., Somogyi, A. A., Barratt, D. T., . . . McNair, P. J. (2022). Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.. Anaesthesia, 77(8), 882-891. Scopus18 WoS18 Europe PMC17 |
| 2021 | Rowsell, L., Wu, J. G. -A., Yee, B. J., Wong, K. K. H., Sivam, S., Somogyi, A. A., . . . Wang, D. (2021). The effect of acute morphine on sleep in male patients suffering from sleep apnea: Is there a genetic effect? An RCT study. Journal of Sleep Research, 30(4), 1-8. Scopus5 WoS2 Europe PMC1 |
| 2021 | Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., . . . Skaar, T. C. (2021). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clinical pharmacology and therapeutics, 110(4), 888-896. Scopus310 WoS277 Europe PMC260 |
| 2021 | Desta, Z., El-Boraie, A., Gong, L., Somogyi, A. A., Lauschke, V. M., Dandara, C., . . . Gaedigk, A. (2021). PharmVar GeneFocus: CYP2B6.. Clin Pharmacol Ther, 110(1), 82-97. Scopus59 WoS54 Europe PMC49 |
| 2021 | Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909. Scopus21 WoS21 Europe PMC14 |
| 2021 | Barratt, D. T., Sia, A. T., Tan, E. -C., & Somogyi, A. A. (2021). Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Medicine, 22(11), 2648-2660. Scopus6 WoS6 Europe PMC5 |
| 2021 | Bordin Andriguetti, N., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci, 110(10), 3362-3366. Scopus5 WoS3 Europe PMC2 |
| 2021 | Bordin Andriguetti, N., Van Schalkwyk, H. K., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 14(6), 2521-2531. Scopus8 WoS8 Europe PMC7 |
| 2021 | Karnes, J. H., Rettie, A. E., Somogyi, A. A., Huddart, R., Fohner, A. E., Formea, C. M., . . . Callaghan, J. T. (2021). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and HLA-B genotypes and phenytoin dosing: 2020 update. Clinical Pharmacology and Therapeutics, 109(2), 302-309. Scopus126 WoS114 Europe PMC104 |
| 2020 | Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8. Scopus4 WoS6 Europe PMC2 |
| 2020 | Suthers, G., & Somogyi, A. A. (2020). Pharmacogenetics of statin intolerance.. Intern Med J, 50(4), 506-507. Scopus3 WoS2 Europe PMC1 |
| 2020 | Somogyi, A. A., Athanasos, P., White, J., Bochner, F., & Ling, W. (2020). Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.. Pain medicine (Malden, Mass.), 21(9), 2007-2008. Scopus1 WoS1 |
| 2019 | Zheng, Z., Gibson, S., Helme, R. D., Wang, Y., Lu, D. S. -C., Arnold, C., . . . Xue, C. C. L. (2019). Effects of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: a multicenter randomized controlled trial. Pain Medicine, 20(2), 397-410. Scopus30 WoS28 Europe PMC29 |
| 2019 | Athanasos, P., Ling, W., Bochner, F., White, J. M., & Somogyi, A. A. (2019). Buprenorphine maintenance subjects are hyperalgesic and have no antinociceptive response to a very high morphine dose. Pain Medicine, 20(1), 119-128. Scopus28 WoS28 Europe PMC22 |
| 2019 | Rowsell, L., Wong, K., Yee, B., Eckert, D., Somogyi, A., Duffin, J., . . . Wang, D. (2019). The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. Thorax, 74(2), 177-184. Scopus35 WoS32 Europe PMC30 |
| 2019 | Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17. Scopus10 WoS10 Europe PMC9 |
| 2019 | Suarez-Kurtz, G., Aklillu, E., Saito, Y., & Somogyi, A. (2019). Conference report: pharmacogenomics in special populations at WCP2018. British Journal of Clinical Pharmacology, 85(3), 467-475. Scopus5 WoS5 Europe PMC5 |
| 2019 | Sallustio, B. C., Noll, B. D., Coller, J. K., Tuke, J., Russ, G., & Somogyi, A. A. (2019). Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation. British Journal of Clinical Pharmacology, 85(5), 1015-1020. Scopus5 WoS3 Europe PMC4 |
| 2019 | Gálvez Ortiz, V., Glue, P., Somogyi, A. A., Martin, D., Alonzo, A., Rodgers, A., . . . Loo, C. K. (2019). A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 33(2), 260-261. |
| 2019 | Chiang, D. L. C., Rice, D. A., Helsby, N. A., Somogyi, A. A., & Kluger, M. T. (2019). The Prevalence, Impact, and Risk Factors for Persistent Pain After Breast Cancer Surgery in a New Zealand Population.. Pain medicine (Malden, Mass.), 20(9), 1803-1814. Scopus26 WoS22 Europe PMC21 |
| 2019 | Somogyi, A. A., Barratt, D. T., Phillips, E. J., Moore, K., Ilyas, F., & Gabb, G. M. (2019). High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology, 85(9), 2163-2169. Scopus23 WoS19 Europe PMC14 |
| 2019 | Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532. Scopus7 WoS7 Europe PMC7 |
| 2018 | Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A., . . . Loo, C. (2018). Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. Scopus79 WoS71 Europe PMC62 |
| 2018 | Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123(3), 320-326. Scopus33 WoS30 Europe PMC28 |
| 2018 | Tucci, J., Pumuye, P., Helsby, N., Barratt, D., Pokeya, P., Hombhanje, F., & Somogyi, A. (2018). Pharmacogenomics in Papua New Guineans: Unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and Genomics, 28(6), 153-164. Scopus8 WoS7 Europe PMC8 |
| 2018 | Licari, G., Milne, R., Somogyi, A., & Sallustio, B. (2018). Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacology Research and Perspectives, 6(3), e00406. Scopus3 WoS3 Europe PMC3 |
| 2018 | Rice, D., Kluger, M., McNair, P., Lewis, G., Somogyi, A., Borotkanics, R., . . . Walker, M. (2018). Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. British Journal of Anaesthesia, 121(4), 804-812. Scopus135 WoS128 Europe PMC96 |
| 2018 | Md Dom, Z., Coller, J., Carroll, R., Tuke, J., McWhinney, B., Somogyi, A., & Sallustio, B. (2018). Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British Journal of Clinical Pharmacology, 84(10), 2433-2442. Scopus19 WoS17 Europe PMC18 |
| 2017 | Currow, D., Watts, G., Johnson, M., McDonald, C., Miners, J., Somogyi, A., . . . Ekström, M. (2017). A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion and Morphine Sulfate (BEAMS) study protocol. BMJ Open, 7(7), e018100-1-e018100-18. Scopus29 WoS30 Europe PMC22 |
| 2017 | Somogyi, A. A., & Phillips, E. (2017). Genomic testing as a tool to optimise drug therapy. Australian Prescriber, 40(3), 101-104. Scopus14 WoS11 |
| 2017 | Barratt, D., & Somogyi, A. (2017). Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 6(S10), 1541-1557. Scopus17 WoS16 |
| 2017 | Newcombe, D., Somogyi, A., Bochner, F., & White, J. (2017). Impaired psychomotor function and plasma methadone and levo-alpha-acetylmethadol (LAAM) concentrations in opioid-substitution patients. Experimental and Clinical Psychopharmacology, 25(3), 223-233. Scopus3 WoS3 Europe PMC1 |
| 2017 | Mackenzie, P., Somogyi, A., & Miners, J. (2017). Advances in drug metabolism and pharmacogenetics research in Australia. Pharmacological Research, 116, 7-19. Scopus12 WoS13 Europe PMC10 |
| 2017 | Glue, P., Loo, C., Rodgers, A., Gálvez, V., Somogyi, A., & Mitchell, P. (2017). Comments on Cooper et al.’s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. World Journal of Biological Psychiatry, 18(6), 489. Scopus2 WoS2 Europe PMC2 |
| 2017 | Gálvez, V., Nikolin, S., Ho, K., Alonzo, A., Somogyi, A., & Loo, C. (2017). Increase in PAS-induced neuroplasticity after a treatment course of intranasal ketamine for depression. Report of three cases from a placebo-controlled trial. Comprehensive Psychiatry, 73, 31-34. Scopus6 WoS6 Europe PMC6 |
| 2017 | Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985. Scopus22 WoS23 Europe PMC20 |
| 2016 | Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466. Scopus25 WoS22 Europe PMC19 |
| 2016 | Loo, C., Gálvez, V., O'Keefe, E., Mitchell, P., Hadzi-Pavlovic, D., Leyden, J., . . . Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. Scopus195 WoS178 Europe PMC145 |
| 2016 | Lewis, B. C., Nair, P. C., Heran, S. S., Somogyi, A. A., Bowden, J. J., Doogue, M. P., & Miners, J. O. (2016). Warfarin resistance associated with genetic polymorphism of VKORC1: Linking clinical response to molecular mechanism using computational modeling. Pharmacogenetics and Genomics, 26(1), 44-50. Scopus14 WoS12 Europe PMC8 |
| 2016 | Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., . . . Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. Scopus198 WoS169 Europe PMC153 |
| 2016 | De Boer, A., Cohen, A. F., Ferro, A., Flockhart, D. A., Gilchrist, A., Isbister, G., . . . Webb, A. J. (2016). Editors' report for 2015, December 2015. British Journal of Clinical Pharmacology, 81(1), 6-7. |
| 2016 | Khan, M., Barratt, D., & Somogyi, A. (2016). Impact of CYP2C8∗3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 46(3), 278-287. Scopus18 WoS16 Europe PMC12 |
| 2015 | Currow, D., Quinn, S., Ekstrom, M., Kaasa, S., Johnson, M., Somogyi, A., & Klepstad, P. (2015). Can variability in the effect of opioids on refractory breathlessness be explained by genetic factors?. BMJ Open, 5(5), e006818-1-e006818-6. Scopus38 WoS33 Europe PMC27 |
| 2015 | Martin, J. H., Phillips, E., Thomas, D., & Somogyi, A. A. (2015). Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes. British Journal of Clinical Pharmacology, 80(5), 929-931. Scopus5 WoS4 Europe PMC3 |
| 2015 | Barratt, D., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. (2015). Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One, 10(9), e0137179-1-e0137179-13. Scopus25 WoS24 Europe PMC16 |
| 2015 | Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127. Scopus39 WoS25 Europe PMC26 |
| 2015 | Li, Y., Jackson, K., Slon, B., Hardy, J., Franco, M., William, L., . . . Somogyi, A. (2015). CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. British Journal of Clinical Pharmacology, 80(2), 276-284. Scopus58 WoS46 Europe PMC47 |
| 2015 | Loke, Y. K., Somogyi, A. A., Ferro, A., & Ritter, J. M. (2015). Editors' pick 2014. British Journal of Clinical Pharmacology, 79(3), 354-356. Scopus1 |
| 2015 | Corrigan, F., Wu, Y., Tuke, J., Coller, J., Rice, K., Diener, K., . . . Hutchinson, M. (2015). Alcohol-induced sedation and synergistic interactions between alcohol and morphine: a key mechanistic role for Toll-like receptors and MyD88-dependent signaling. Brain, Behavior, and Immunity, 45, 245-252. Scopus22 WoS22 Europe PMC21 |
| 2015 | Loke, Y. K., Cohen, A. F., Ferro, A., Flockhart, D. A., Ritter, J. M., & Somogyi, A. A. (2015). Editors' report for 2014, November 2014. British Journal of Clinical Pharmacology, 79(1), 4-5. |
| 2015 | Licari, G., Somogyi, A., Milne, R., & Sallustio, B. (2015). Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague-Dawley and Dark Agouti rats. Xenobiotica, 45(1), 3-9. Scopus3 WoS3 Europe PMC1 |
| 2014 | Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027. Scopus43 WoS41 Europe PMC38 |
| 2014 | Dooney, N., Sundararajan, K., Ramkumar, T., Somogyi, A., Upton, R., Ong, J., . . . Ludbrook, G. (2014). Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. BMC Anesthesiology, 14(article no. 33), 33-1-33-8. Scopus8 WoS8 Europe PMC8 |
| 2014 | Somogyi, A. A., Lewis, L. D., Cohen, A. F., Flockhart, D. A., Ferro, A., Loke, Y. K., & Ritter, J. M. (2014). Editors' report, November 2013. British Journal of Clinical Pharmacology, 77(3), 401-402. |
| 2014 | Gálvez, V., O'Keefe, E., Cotiga, L., Leyden, J., Harper, S., Glue, P., . . . Loo, C. K. (2014). Long-lasting effects of a single subcutaneous dose of Ketamine for treating melancholic depression: A case report. Biological Psychiatry, 76(3), e1-e2. Scopus36 WoS31 Europe PMC24 |
| 2014 | Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506. Scopus17 WoS12 Europe PMC13 |
| 2014 | Md Dom, Z., Noll, B., Coller, J., Somogyi, A., Russ, G., Hesselink, D., . . . Sallustio, B. (2014). Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. Journal of Chromatography B, 945-946, 171-177. Scopus22 WoS20 Europe PMC13 |
| 2014 | Gilchrist, A., Loke, Y. K., Somogyi, A. A., Cohen, A. F., & Ritter, J. M. (2014). BJCP 40th anniversary: Moving forward, looking back. British Journal of Clinical Pharmacology, 78(6), 1175-1184. |
| 2014 | Lai, R., Katalinic, N., Glue, P., Somogyi, A., Mitchell, P., Leyden, J., . . . Loo, C. (2014). Pilot dose-response trial of I.V. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry, 15(7), 579-584. Scopus83 WoS74 Europe PMC62 |
| 2014 | Barratt, D., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L., . . . Somogyi, A. (2014). Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 24(4), 185-194. Scopus54 WoS44 Europe PMC38 |
| 2014 | Ferro, A., Loke, Y. K., Lewis, L. D., Somogyi, A., Cohen, A. F., & Ritter, J. M. (2014). Editors' pick 2013. British Journal of Clinical Pharmacology, 77(2), 228-232. |
| 2013 | Katalinic, K., Lai, R., Somogyi, A., Mitchell, P., Glue, P., & Loo, C. (2013). Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Australian and New Zealand Journal of Psychiatry, 47(8), 710-727. Scopus107 WoS96 Europe PMC79 |
| 2013 | Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2013). Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Therapeutic Drug Monitoring, 35(5), 617-623. Scopus34 WoS31 Europe PMC30 |
| 2013 | Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Stanley, N., . . . Somogyi, A. (2013). The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metabolism and Disposition, 41(6), 1264-1272. Scopus43 WoS37 Europe PMC31 |
| 2013 | Wang, D., Somogyi, A., Yee, B., Wong, K., Kaur, J., Wrigley, P., & Grunstein, R. (2013). The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. Respiratory Physiology and Neurobiology, 185(3), 526-532. Scopus44 WoS39 Europe PMC42 |
| 2013 | Maddison, J., Somogyi, A., Jensen, B., James, H., Gentgall, M., & Rolan, P. (2013). The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype. British Journal of Clinical Pharmacology, 75(1), 208-216. Scopus34 WoS30 Europe PMC26 |
| 2013 | Loke, Y. K., Cohen, A. F., Ferro, A., Lewis, L. D., Ritter, J. M., & Somogyi, A. A. (2013). Editors' Report, 2012. British Journal of Clinical Pharmacology, 75(2), 301-302. |
| 2013 | Lewis, L. D., Somogyi, A., Loke, Y. K., Ferro, A., Cohen, A. F., & Ritter, J. M. (2013). Editors' pick 2012.. British Journal of Clinical Pharmacology, 75(1), 1-6. |
| 2012 | Xue, C., Helme, R., Gibson, S., Hogg, M., Arnold, C., Somogyi, A., . . . Lu, S. (2012). Effect of electroacupuncture on opioid consumption in patients with chronic musculoskeletal pain: protocol of a randomised controlled trial. Trials, 13(1), 1-8. Scopus15 WoS13 Europe PMC10 |
| 2012 | Duley, J., Somogyi, A., & Martin, J. (2012). The future of thiopurine pharmacogenomics. Pharmagenomics, 13(14), 1549-1552. Scopus14 WoS12 Europe PMC12 |
| 2012 | Coller, J., Michalakas, J., James, H., Farquharson, A., Colvill, J., White, J., & Somogyi, A. (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British Journal of Clinical Pharmacology, 74(5), 835-841. Scopus22 WoS18 Europe PMC15 |
| 2012 | Dale, O., Somogyi, A., Li, Y., Sullivan, T., & Shavit, Y. (2012). Does intraoperative ketamine attenuate inflammatory reactivity following surgery?: a systematic review and meta-analysis. Anesthesia and Analgesia, 115(4), 934-943. Scopus213 WoS182 Europe PMC161 |
| 2012 | Hutchinson, M., Northcutt, A., Hiranita, T., Wang, X., Lewis, S., Thomas, J., . . . Watkins, L. (2012). Opioid activation of toll-like receptor 4 contributes to drug reinforcement. Journal of Neuroscience, 32(33), 11187-11200. Scopus258 WoS248 Europe PMC230 |
| 2012 | Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62. Scopus48 WoS43 Europe PMC38 |
| 2012 | Wang, J., Hughes, T., Kok, C., Saunders, V., Frede, A., Groot Obbink, K., . . . White, D. (2012). Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells. British Journal of Cancer, 106(11), 1772-1778. Scopus21 WoS19 Europe PMC17 |
| 2012 | Wang, X., Loram, L., Ramos, K., de Jesus, A., Thomas, J., Cheng, K., . . . Yin, H. (2012). Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings of the National Academy of Sciences of the United States of America, 109(16), 6325-6330. Scopus413 WoS406 Europe PMC364 |
| 2012 | Gelston, E., Coller, J., Lopatko, O., James, H., Schmidt, H., White, J., & Somogyi, A. (2012). Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology, 73(5), 786-794. Scopus28 WoS25 Europe PMC21 |
| 2012 | Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Coller, J., Rice, K., . . . Hutchinson, M. (2012). Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. British Journal of Pharmacology, 165(5), 1319-1329. Scopus69 WoS59 Europe PMC60 |
| 2012 | Savvas, S., Somogyi, A., & White, J. (2012). The effect of methadone on emotional reactivity. Addiction, 107(2), 388-392. Scopus21 WoS18 Europe PMC11 |
| 2012 | Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2012). Editors' pick 2011. British Journal of Clinical Pharmacology, 73(1), 4-8. Scopus1 WoS1 |
| 2012 | Somogyi, A., Lewis, L., Cohen, A., Ferro, A., Loke, Y., & Ritter, J. (2012). Editors' report, November 2011. British Journal of Clinical Pharmacology, 73(2), 159-160. |
| 2011 | Noll, B., Coller, J., Somogyi, A., Morris, R., Russ, G., Hesselink, D., . . . Sallustio, B. (2011). Measurement of Cyclosporine A in rat tissues and human kidney transplant biopsies - A method suitable for small (<1 mg) samples. Therapeutic Drug Monitoring, 33(6), 688-693. Scopus15 WoS15 Europe PMC14 |
| 2011 | Coller, J., Cahill, S., Edmonds, C., Farquharson, A., Longo, M., Minniti, R., . . . White, J. (2011). OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 21(12), 902-905. Scopus40 WoS34 Europe PMC32 |
| 2011 | Huxtable, C., Roberts, L., Somogyi, A., & Macintyre, P. (2011). Acute pain management in opioid-tolerant patients: a growing challenge. Anaesthesia and Intensive Care, 39(5), 804-823. Scopus201 WoS165 Europe PMC129 |
| 2011 | Liu, L., Coller, J., Watkins, L., Somogyi, A., & Hutchinson, M. (2011). Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains. Brain Behavior and Immunity, 25(6), 1223-1232. Scopus56 WoS54 Europe PMC52 |
| 2011 | Hay, J., La Vincente, S., Somogyi, A., Chapleo, C., & White, J. (2011). Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects. European Journal of Pain, 15(3), 293-298. Scopus16 WoS13 Europe PMC12 |
| 2011 | Wu, Y., Lousberg, E., Moldenhauer, L., Hayball, J., Robertson, S., Coller, J., . . . Hutchinson, M. (2011). Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment. Brain Behavior and Immunity, 25(Suppl 1), 155-164. Scopus71 WoS54 Europe PMC61 |
| 2011 | Grace, P., Hutchinson, M., Bishop, A., Somogyi, A., Mayrhofer, G., & Rolan, P. (2011). Adoptive transfer of peripheral immune cells potentiates allodynia in a graded chronic constriction injury model of neuropathic pain. Brain Behavior and Immunity, 25(3), 503-513. Scopus24 WoS22 Europe PMC21 |
| 2011 | Becquement, L., Alfirevic, A., Amstutz, U., Brauch, H., Jacqz-Algrain, E., Laurent-Puig, P., . . . Daly, A. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics, 12(1), 113-124. Scopus95 WoS72 Europe PMC61 |
| 2011 | Loke, Y. K., Ferro, A., Lewis, L. D., Cohen, A. F., Somogyi, A., & Ritter, J. M. (2011). Editors' pick 2010. British Journal of Clinical Pharmacology, 71(1), 3-6. |
| 2011 | Licari, G., Somogyi, A. A., Milne, R. W., & Sallustio, B. C. (2011). MYOCARDIAL AND HEPATIC DISPOSITION OF THE ENANTIOMERS OF PERHEXILINE. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 109, 152. |
| 2011 | Cohen, A. F., Loke, Y. K., Ferro, A., Lewis, L. D., Somogy, A., & Ritter, J. M. (2011). Editors' report, November 2010. British Journal of Clinical Pharmacology, 71(1), 1-2. |
| 2010 | Somogyi, A., & Hardy, J. (2010). Role of pharmacogenomics in pain therapy: Focus on opioids. Cancer Forum, 34(2), 74-77. Scopus1 WoS1 |
| 2010 | Gordon, A., Lopatko, O., Somogyi, A., Foster, D., & White, J. (2010). (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. British Journal of Clinical Pharmacology, 70(6), 895-902. Scopus31 WoS29 Europe PMC24 |
| 2010 | Grace, P., Hutchinson, M., Manavis, J., Somogyi, A., & Rolan, P. (2010). A novel animal model of graded neuropathic pain: Utility to investigate mechanisms of population heterogeneity. Journal of Neuroscience Methods, 193(1), 47-53. Scopus47 WoS47 Europe PMC43 |
| 2010 | Upton, R., Somogyi, A., Martinez, A., Colvill, J., & Grant, C. (2010). Pharmacokinetics and pharmacodynamics of the short-acting sedative CNS 7056 in sheep. British Journal of Anaesthesia, 105(6), 798-809. Scopus44 WoS43 Europe PMC36 |
| 2010 | Raungrut, P., Uchaipichat, V., Elliot, D., Janchawee, B., Somogyi, A., & Miners, J. (2010). In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. Journal of Pharmacology and Experimental Therapeutics, 334(2), 609-618. Scopus74 WoS72 Europe PMC56 |
| 2010 | Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2010). Editors' pick 2009. British Journal of Clinical Pharmacology, 69(2), 107-110. |
| 2010 | Loke, Y., Cohen, A., Ferro, A., Lewis, L., Ritter, J., & Somogyi, A. (2010). British Journal of Clinical Pharmacology: Editors' Report, November 2009. British Journal of Clinical Pharmacology, 69(1), 1. |
| 2010 | Somogyi, A., Loke, Y., Ferro, A., Lewis, L., Cohen, A., & Ritter, J. (2010). Clinical pharmacology: A declaration of intent. British Journal of Clinical Pharmacology, 70(1), 1-2. Scopus3 WoS3 Europe PMC3 |
| 2010 | Hutchinson, M., Lewis, S., Coats, B., Rezvani, N., Zhang, Y., Wieseler, J., . . . Watkins, L. (2010). Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience, 167(3), 880-893. Scopus117 WoS107 Europe PMC102 |
| 2009 | Coller, J., Beardsley, J., Bignold, J., Li, Y., Merg, F., Sullivan, T., . . . Somogyi, A. (2009). Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis. Pharmacogenomics and Personalized Medicine, 2(1), 9-19. Scopus28 WoS24 |
| 2009 | Liu, L., Hutchinson, M., White, J., Somogyi, A., & Coller, J. (2009). Association of IL-1B genetic polymorphisms with an increased risk of opioid and alcohol dependence. Pharmacogenetics and Genomics (Print Edition), 19(11), 869-876. Scopus42 WoS38 Europe PMC38 |
| 2009 | Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A., . . . Eschalier, A. (2009). Dépendance aux benzodiazépines : le syndrome de sevrage. Annales Pharmaceutiques Francaises, 67(6), 408-413. Scopus53 Europe PMC32 |
| 2009 | Hallinan, R., Crettol, S., Agho, K., Attia, J., Besson, J., Croquette-Krokar, M., . . . Eap, C. (2009). Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. European Journal of Clinical Pharmacology, 65(11), 1113-1120. Scopus16 WoS14 Europe PMC11 |
| 2009 | Bell, J., Shearer, J., Ryan, A., Graham, R., Korompay, K., Rizzo, S., . . . Somogyi, A. (2009). The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio. Experimental and Clinical Psychopharmacology, 17(3), 146-153. Scopus8 WoS6 Europe PMC7 |
| 2009 | Ozdemir, V., Suarez-Kurtz, G., Stenne, R., Somogyi, A., Someya, T., Kayaalp, S., & Kolker, E. (2009). Risk assessment and communication tools for genotype associations with multifactorial phenotypes: The concept of "edge effect" and cultivating an ethical bridge between omics innovations and society. OMICS: A Journal of Integrative Biology, 13(1), 43-61. Scopus59 WoS38 Europe PMC34 |
| 2009 | Hay, J., White, J., Bochner, F., Somogyi, A., Semple, T., & Rousefell, B. (2009). Hyperalgesia in Opioid-Managed Chronic Pain and Opioid-Dependent Patients. The Journal of Pain, 10(3), 316-322. Scopus140 WoS116 Europe PMC95 |
| 2009 | Cohen, A., Loke, Y., Lewis, L., Schachter, M., Somogyi, A., & Ritter, J. (2009). Editors' Report, December 2008. British Journal of Clinical Pharmacology, 67(2), 151-152. |
| 2009 | Coller, J., Christrup, L., & Somogyi, A. (2009). Role of active metabolites in the use of opioids. European Journal of Clinical Pharmacology, 65(2), 121-139. Scopus102 WoS78 Europe PMC60 |
| 2009 | Doogue, M., Martin, J., Miners, J., & Somogyi, A. (2009). Prescribing in liver disease [1]. Australian Prescriber, 32(5), 120. Scopus1 WoS1 |
| 2009 | Somogyi, A. (2009). Warfarin pharmacogenetics. Australian Prescriber, 32(5), 119. |
| 2009 | Loke, Y. K., Somogyi, A., Lewis, L. D., Schachter, M., Cohen, A. F., & Ritter, J. M. (2009). Looking back: Editors' pick of 2008. British Journal of Clinical Pharmacology, 67(1), 1-4. Scopus3 WoS3 Europe PMC3 |
| 2008 | Hutchinson, M., Coats, B., Lewis, S., Zhang, Y., Sprunger, D., Rezvani, N., . . . Watkins, L. (2008). Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behavior and Immunity, 22(8), 1178-1189. Scopus275 WoS247 Europe PMC233 |
| 2008 | Somogyi, A., Larsen, M., Abadi, R., Jittiwutikarn, J., Ali, R., & White, J. (2008). Flexible dosing of Tincture of Opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology, 66(5), 640-647. Scopus19 WoS20 Europe PMC15 |
| 2008 | Hay, J., White, J., Bochner, F., & Somogyi, A. (2008). Antinociceptive effects of high dose remifentanil in male methadone-maintained patients. European Journal of Pain, 12(7), 926-933. Scopus19 WoS17 Europe PMC11 |
| 2008 | Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670. Scopus3 WoS2 |
| 2008 | James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2008). Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. Journal of Rheumatology, 35(4), 562-571. Scopus57 WoS57 Europe PMC45 |
| 2008 | Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 65(3), 347-354. Scopus8 WoS8 Europe PMC6 |
| 2008 | La Vincente, S., White, J., Somogyi, A., Bochner, F., & Chapleo, C. (2008). Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clinical Pharmacology & Therapeutics, 83(1), 144-152. Scopus29 WoS19 Europe PMC15 |
| 2008 | Somogyi, A. (2008). Evolution of Pharmacogenomics. Western Pharmacology Society. Proceedings, 51, 1-4. Scopus12 Europe PMC11 |
| 2007 | Coller, J., Joergensen, C., Foster, D., James, H., Gillis, D., Christrup, L., & Somogyi, A. (2007). Lack of influence of CYP2D6 genotype on the clearance of (R)- (S)- and racemic-methadon. International Journal of Clinical Pharmacology and Therapeutics, 45(7), 410-417. Scopus25 WoS22 Europe PMC19 |
| 2007 | Igel, S., Drescher, S., Murdter, T., Hofmann, U., Heinkele, G., Tegude, H., . . . Fromm, M. (2007). Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clinical Pharmacokinetics, 46(9), 777-785. Scopus67 WoS57 Europe PMC50 |
| 2007 | Jensen, M., Foster, D., Upton, R., Grant, C., Martinez, A., & Somogyi, A. (2007). Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica, 37(4), 441-457. Scopus22 WoS20 Europe PMC20 |
| 2007 | Inglis, S., Herbert, M., Davies, B., Coller, J., James, H., Horowitz, J., . . . Sallustio, B. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (-) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics (Print Edition), 17(5), 305-312. Scopus8 WoS7 Europe PMC4 |
| 2007 | Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444. Scopus302 WoS250 Europe PMC194 |
| 2007 | Davies, B., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2007). CYP2B6 CYP2D6 and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metabolism and Disposition, 35(1), 128-138. Scopus24 WoS23 Europe PMC20 |
| 2006 | Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690. Scopus137 WoS117 Europe PMC101 |
| 2006 | Davies, B., Herbert, M., Coller, J., Somogyi, A., Milne, R., & Sallustio, B. (2006). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 843(2), 302-309. Scopus9 WoS10 Europe PMC4 |
| 2006 | Villesen, H., Foster, D., Upton, R., Christrup, L., Somogyi, A., Martinez, A., & Grant, C. (2006). Blood-brain distribution of morphine-6-glucuronide in sheep. British Journal of Pharmacology, 149(6), 754-760. Scopus3 WoS3 Europe PMC1 |
| 2006 | Foster, D., Morton, E., Heinkele, G., Murdter, T., & Somogyi, A. (2006). Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: Application to a pharmacokinetic study in a methadone maintained subject. Therapeutic Drug Monitoring, 28(4), 559-567. Scopus13 WoS11 Europe PMC11 |
| 2006 | Villesen, H., Foster, D., Upton, R., Somogyi, A., Martinez, A., & Grant, C. (2006). Cerebral kinetics of oxycodone in conscious sheep. Journal of Pharmaceutical Sciences, 95(8), 1666-1676. Scopus24 WoS23 Europe PMC21 |
| 2006 | Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2006). Switching between methadone and morphine for maintenance treatment of opioid dependence: Impact on pain sensitivity and mood status. American Journal on Addictions, 15(4), 311-315. Scopus16 WoS13 Europe PMC12 |
| 2006 | Mitchell, T., Dyer, K., Newcombe, D., Somogyi, A., & White, J. (2006). Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients. Addiction Biology, 11(2), 170-174. Scopus5 WoS3 Europe PMC5 |
| 2006 | Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331. Scopus49 WoS45 Europe PMC45 |
| 2006 | Polasek, T., Elliot, D., Somogyi, A., Gillam, E., Lewis, B., & Miners, J. (2006). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. British Journal of Clinical Pharmacology, 61(5), 570-584. Scopus68 WoS60 Europe PMC46 |
| 2006 | Athanasos, P., Smith, C., White, J., Somogyi, A., Bochner, F., & Ling, W. (2006). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain, 120(3), 267-275. Scopus90 WoS76 Europe PMC70 |
| 2006 | Davies, B., Herbert, M., Culbert, J., Pyke, S., Coller, J., Somogyi, A., . . . Sallustio, B. (2006). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 832(1), 114-120. Scopus17 WoS15 Europe PMC10 |
| 2006 | Foster, D., Jensen, M., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2006). Blood-brain equilibration kinetics of levo-alpha-acetyl-methadol using a chronically instrumented sheep preparation. British Journal of Pharmacology, 147(2), 209-217. Scopus3 WoS3 Europe PMC3 |
| 2006 | Morrish, G., Foster, D., & Somogyi, A. (2006). Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids. British Journal of Clinical Pharmacology, 61(3), 326-335. Scopus15 WoS15 Europe PMC14 |
| 2006 | Somogyi, A. (2006). Serotonin syndrome [1]. Australian Prescriber, 29(6), 149. |
| 2006 | Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229. |
| 2006 | Coller, J. K., Plevin, D., Sallustio, B. C., Somogyi, A. A., & Morris, R. G. (2006). Relationship between the ABCB1 genetic polymorphism and clinical outcomes in renal transplant patients.. ACTA PHARMACOLOGICA SINICA, 27, 229. |
| 2005 | Foster, D., Upton, R., Somogyi, A., Grant, C., & Martinez, A. (2005). The acute disposition of (R)- and (S)-methadone in brain and lung of sheep. Journal of Pharmacokinetics and Pharmacodynamics, 32(3-4), 547-570. Scopus9 WoS8 Europe PMC7 |
| 2005 | Hanna, J., Foster, D., Salter, A., Somogyi, A., White, J., & Bochner, F. (2005). Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects. British Journal of Clinical Pharmacology, 60(4), 404-413. Scopus24 WoS23 Europe PMC16 |
| 2005 | Hutchinson, M., & Somogyi, A. (2005). Characterisation of the in vitro modulation of splenocyte proliferation by non-4,5-epoxymorphinan opioids. International Immunopharmacology, 5(12), 1713-1722. Scopus6 WoS4 Europe PMC4 |
| 2005 | Davies, B., Coller, J., James, H., Somogyi, A., Horowitz, J., & Sallustio, B. (2005). The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia. British Journal of Clinical Pharmacology, 61(3), 321-325. Scopus12 WoS13 Europe PMC6 |
| 2005 | Somogyi, A. (2005). Erratum: Inside the isomers: The tale of chiral switches (Australian Prescriber (2004) 27 (47-49)). Australian Prescriber, 28(3), 58. |
| 2005 | Somogyi, A. (2005). Isomers - Correction [5]. Australian Prescriber, 28(3), 58. |
| 2005 | Somogyi, A. (2005). Inside the isomers: the tale of chiral switches(vol27, pg 47, 2004). AUSTRALIAN PRESCRIBER, 28(3), 58. WoS1 |
| 2004 | Lanternier, F., Somogyi, A., Kahn, J. E., & Leport, J. (2004). Acute necrosing esophagitis during alcohol detoxication. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 28(12), 1299-1300. WoS1 |
| 2004 | Pelser, D., & Somogyi, A. (2004). Inside the isomers: The tale of chiral switches [2] (multiple letters). Australian Prescriber, 27(5), 110. |
| 2004 | Somogyi, A., Bochner, F., & Foster, D. (2004). Inside the isomers: the tale of chiral switches. Australian Prescriber, 27(2), 47-49. Scopus36 |
| 2004 | Glaeser, H., Drescher, S., Hofmann, U., Heinkele, G., Somogyi, A., Eichelbaum, M., & Fromm, M. (2004). Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clinical Pharmacology & Therapeutics, 76(3), 230-238. Scopus31 WoS26 Europe PMC20 |
| 2004 | Athanasos, P., Morrish, G., Somogyi, A., Bochner, F., & White, J. (2004). Changes in methadone concentration, opiod effects, and opioid withdrawal during induction onto maintenance treatment. Addictive Disorders & Their Treatment, 3(3), 122-128. |
| 2004 | Hutchinson, M., & Somogyi, A. (2004). (S)-(+)methadone is more immunosuppressive than the potent analgesic (R)-(-)-methadone. International Immunopharmacology, 4(12), 1525-1530. Scopus13 WoS12 Europe PMC11 |
| 2004 | Hutchinson, M., La Vincente, S., & Somogyi, A. (2004). In vitro opioid induced proliferation of peripheral blood immune cells correlates with in vivo cold pressor pain tolerance in humans: a biological marker of pain tolerance. Pain, 110(3), 751-755. Scopus13 WoS11 Europe PMC10 |
| 2004 | Newcombe, D., Bochner, F., White, J., & Somogyi, A. (2004). Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence, 76(1), 63-72. Scopus24 WoS20 Europe PMC13 |
| 2004 | Mitchell, T., Dyer, K., Newcombe, D., Salter, A., Somogyi, A., Bochner, F., & White, J. (2004). Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. British Journal of Clinical Pharmacology, 58(6), 609-617. Scopus47 WoS40 Europe PMC31 |
| 2004 | Somogyi, A., Menelaou, A., & Fullston, S. (2004). CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica, 34(10), 875-887. Scopus16 WoS12 Europe PMC9 |
| 2004 | James, H., Coller, J., Gillis, D., Bahnisch, J., Sallustio, B., & Somogyi, A. (2004). A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis. International Journal of Clinical Pharmacology and Therapeutics, 42(12), 719-723. Scopus19 WoS15 Europe PMC11 |
| 2004 | Jittiwutikarn, J., Ali, R., White, J., Bochner, F., Somogyi, A., & Foster, D. (2004). Comparison of tincture of opium and methadone to control opioid withdrawal in a Thai treatment centre. British Journal of Clinical Pharmacology, 58(5), 536-541. Scopus20 WoS17 Europe PMC11 |
| 2004 | Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2004). Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction, 99(8), 940-945. Scopus65 WoS60 Europe PMC46 |
| 2004 | Hutchinson, M., & Somogyi, A. (2004). Relationship between 4,5-epoxymorphinan structure and in vitro modulation of cell proliferation. European Journal of Pharmacology, 494(2-3), 251-262. Scopus10 WoS8 Europe PMC8 |
| 2004 | Foster, D., Somogyi, A., White, J., & Bochner, F. (2004). Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 57(6), 742-755. Scopus72 WoS61 Europe PMC52 |
| 2004 | Davies, B., Coller, J., James, H., Gillis, D., Somogyi, A., Horowitz, J., . . . Sallustio, B. (2004). Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline. British Journal of Clinical Pharmacology, 57(4), 456-463. Scopus6 WoS6 Europe PMC6 |
| 2004 | Hutchinson, M., Menelaou, A., Foster, D., Coller, J., & Somogyi, A. (2004). CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British Journal of Clinical Pharmacology, 57(3), 287-297. Scopus141 WoS107 Europe PMC86 |
| 2003 | Mitchell, T., White, J., Somogyi, A., & Bochner, F. (2003). Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence, 72(1), 85-94. Scopus50 WoS45 Europe PMC36 |
| 2003 | Gross, A., Somogyi, A., & Eichelbaum, M. (2003). Stereoselective drug metabolism and drug interactions. Handbook of Experimental Pharmacology, 153, 313-339. |
| 2003 | Menelaou, A., Hutchinson, M., Quinn, I., Christensen, A., & Somogyi, A. (2003). Quantification of the O- and N-demethylated metabolites of hydrocodone and oxycodone in human liver microsomes using liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 785(1), 81-88. Scopus23 WoS19 Europe PMC14 |
| 2003 | Sorensen, L., Sorensen, R., Miners, J., Somogyi, A., Grgurinovich, N., & Birkett, D. (2003). Polymorphic hydroxylation of perhexiline in vitro. British Journal of Clinical Pharmacology, 55(6), 635-638. Scopus32 WoS31 Europe PMC25 |
| 2003 | Sallustio, B., Davies, B., Coller, J., James, H., Gillis, D., & Somogyi, A. (2003). Relationship between CYP2D6 genotype and plasma OH-perhexiline/perhexiline concentration ratio in angina patients.. Therapeutic Drug Monitoring, 25(4), 519. |
| 2002 | Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2002). Reply to Dr. Clark's comment on Doverty et al., hyperalgesic responses in methadone maintenance patients (Pain 2001;90 : 91-96). Pain, 99(3), 609-610. WoS1 |
| 2002 | Glaeser, H., Drescher, S., Van der Kuip, H., Behrens, C., Geick, A., Burk, O., . . . Fromm, M. (2002). Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clinical Pharmacology & Therapeutics, 71(3), 131-140. Scopus46 WoS42 Europe PMC30 |
| 2002 | Porter, S., Somogyi, A., & White, J. (2002). In vivo and in vitro potency studies of 6b-naltrexol, the major human metabolite of naltrexone. Addiction Biology, 7(2), 219-225. Scopus44 WoS39 Europe PMC35 |
| 2002 | Hutchinson, M., & Somogyi, A. (2002). Diacetylmorphine degradation to 6-monoacetylmorphine and morphine in cell culture: implications for in vitro studies. European Journal of Pharmacology, 453(1), 27-32. Scopus18 WoS18 Europe PMC14 |
| 2002 | Olver, I., Hercus, T., Lopez, A., Vadas, M., Somogyi, A., Doyle, I., . . . Wigley, P. (2002). A phase I study of the GM-CSF antagonist E21R. Cancer Chemotherapy and Pharmacology, 50(3), 171-178. Scopus8 WoS8 Europe PMC7 |
| 2001 | Doverty, M., Somogyi, A., White, J., Bochner, F., Beare, C., Menelaou, A., & Ling, W. (2001). Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain, 93(2), 155-163. Scopus153 WoS127 Europe PMC104 |
| 2001 | Doverty, M., White, J., Somogyi, A., Bochner, F., Ali, R., & Ling, W. (2001). Hyperalgesic responses in methadone maintenance patients. Pain, 90(01-Feb), 91-96. Scopus276 WoS223 Europe PMC203 |
| 2001 | Dyer, K., White, J., Foster, D., Bochner, F., Menelaou, A., & Somogyi, A. (2001). The relationship between mood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology, 21(1), 78-84. Scopus65 WoS55 Europe PMC44 |
| 2001 | Chew, M., White, J., Somogyi, A., Bochner, F., & Irvine, R. (2001). Precipitated withdrawal following codeine administration is dependent on CYP genotype. European Journal of Pharmacology, 425(3), 159-164. Scopus8 WoS7 Europe PMC6 |
| 2001 | von Richter, O., Greiner, B., Fromm, M., Fraser, R., Omari, T., Barclay, M., . . . Eichelbaum, M. (2001). Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clinical Pharmacology & Therapeutics, 70(3), 217-227. Scopus101 WoS81 Europe PMC61 |
| 2001 | Ling, M., Duncan, E., Rodgers, S., Somogyi, A., Crabb, G., Street, A., & Lloyd, J. (2001). Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. British Journal of Haematology, 114(4), 861-867. Scopus21 WoS16 Europe PMC14 |
| 2001 | Müzes, G., Pitlik, E., Somogyi, A., & Tulassay, Z. (2001). Mild thrombocytopenia as presenting symptom of type 1 Gauchers's disease. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 39(6), 471-+. |
| 2000 | Van Crugten, J., Somogyi, A., & Nation, R. (2000). Effect of uranyl nitrate-induced renal failure on morphine disposition and antiociceptive response response in rats. Clinical and Experimental Pharmacology and Physiology, 27(1-2), 74-79. Scopus6 WoS7 Europe PMC5 |
| 2000 | Foster, D., Somogyi, A., & Bochner, F. (2000). Stereoselective quantification of methadone and its major oxidative metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, in human urine using high-performance liquid chromatography. Journal of Chromatography. B, Analytical Techniques in the Biomedical and Life Sciences, 744(1), 165-176. Scopus34 WoS32 Europe PMC20 |
| 2000 | Porter, S., Somogyi, A., & White, J. (2000). Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. British Journal of Clinical Pharmacology, 50(5), 465-471. Scopus58 WoS54 Europe PMC42 |
| 2000 | Norman, R., Buchholz, M., Somogyi, A., & Amato, F. (2000). hCG core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG. Journal of Endocrinology, 164, 299-305. |
| 2000 | Foster, D., Somogyi, A., Dyer, K., White, J., & Bochner, F. (2000). Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. British Journal of Clinical Pharmacology, 50(5), 427-440. Scopus125 WoS107 Europe PMC86 |
| 2000 | Norman, R. J., Buchholz, M. M., Somogyi, A. A., & Amato, F. (2000). hCGβ core fragment is a metabolite of hCG: Evidence from infusion of recombinant hCG. Journal of Endocrinology, 164(3), 299-305. Scopus25 WoS19 Europe PMC15 |
| 1999 | Greiner, B., Richter, O. V., Omari, T., Dent, J., Somogyi, A., & Eichelbaum, M. (1999). Shedded enterocytes as an ex vivo probe for gut wall metabolism. Clinical Pharmacology and Therapeutics, 65(2), 127. Scopus1 WoS1 |
| 1999 | Von Richter, O., Greiner, B., Omari, T., Dent, J., Somogyi, A., & Eichelbaum, M. (1999). Metabolism and transport of drugs in the human intestine studied with a perfusion catheter. Clinical Pharmacology and Therapeutics, 65(2), 127. Scopus2 WoS1 |
| 1999 | Coller, J., Somogyi, A., & Bochner, F. (1999). Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica, 29(10), 973-986. Scopus33 WoS29 Europe PMC22 |
| 1999 | Malpass, A., White, J., Irvine, R., Somogyi, A., & Bochner, F. (1999). Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti Rats. Pharmacology, Biochemistry and Behavior, 64(1), 29-34. Scopus47 WoS45 Europe PMC41 |
| 1999 | Menelaou, A., Somogyi, A., Barclay, M., & Bochner, F. (1999). Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection. Journal of Chromatography B, 731(2), 261-266. Scopus64 WoS57 Europe PMC28 |
| 1999 | Dyer, K., Foster, D., White, J., Somogyi, A., Menelaou, A., & Bochner, F. (1999). Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics, 65(6), 685-694. Scopus128 WoS117 Europe PMC93 |
| 1999 | Bochner, F., Somogyi, A., Christrup, L., Larsen, U., Danz, C., & Elbaek, K. (1999). Comparative pharmacokinetics of two modified-release oral morphine formulations (Reliadol and Kapanol) and an immediate-release morphine tablet (Morfin 'DAK') in healthy volunteers.. Clinical Drug Investigation, 17(1), 59-66. Scopus8 WoS5 |
| 1999 | Foster, D., Somogyi, A., & Bochner, F. (1999). Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.. British Journal of Clinical Pharmacology, 47(4), 403-412. Scopus177 WoS156 Europe PMC120 |
| 1999 | Coller, J., Somogyi, A., & Bochner, F. (1999). Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.. British Journal of Clinical Pharmacology, 48(2), 158-167. Scopus42 WoS35 Europe PMC29 |
| 1998 | Kirkwood, L., Nation, R., & Somogyi, A. (1998). Glucuronidation of dihydrocodeine by human liver microsomes and the effect of inhibitors.. Clinical and Experimental Pharmacology and Physiology, 25(3-4), 266-270. Scopus29 WoS24 Europe PMC17 |
| 1998 | Coller, J., Somogyi, A., & Bochner, F. (1998). Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high performance liquid chromatography.. Journal of Chromatography B.., 719(1-2), 87-92. Scopus12 WoS11 Europe PMC7 |
| 1998 | Wood, M., Ashby, M., Somogyi, A., & Fleming, B. (1998). Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine. Journal of Pain and Symptom Management, 16(2), 112-120. Scopus32 WoS26 Europe PMC27 |
| 1998 | Foster, D. J. R., Somogyi, A. A., White, J., Dyer, K. R., & Bocher, F. (1998). Pharmacokinetics of (R)- and (S)-methadone in methadone maintenance population. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R461. |
| 1998 | Coller, J. K., Somogyi, A. A., & Bochner, F. (1998). Flunitrazepam oxidative metabolism in human liver microsomes. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 358(1), R421. |
| 1997 | Kirkwood, L., Nation, R., & Somogyi, A. (1997). Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine.. British Journal of Clinical Pharmacology, 44(6), 549-555. Scopus57 WoS41 Europe PMC30 |
| 1997 | Coller, J., Somogyi, A., & Bochner, F. (1997). Association between CYP2C19 genotype and proguanil oxidative polymorphism.. British Journal of Clinical Pharmacology, 43(6), 659-660. Scopus24 WoS20 Europe PMC16 |
| 1997 | Ashby, M., Fleming, B., Wood, M., & Somogyi, A. (1997). Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. Journal of Pain and Symptom Management, 14(3), 157-167. Scopus95 WoS69 Europe PMC62 |
| 1997 | Kirkwood, L., Nation, R., & Somogyi, A. (1997). Determination of the dihydrocodeine metabolites, dihydromorphine and nordihydrocodeine, in hepatic microsomal incubations by high performance liquid chromatography. Journal of Chromatography B: Biomedical Sciences and Applications, 701(1), 129-134. Scopus7 WoS6 Europe PMC2 |
| 1997 | Van Crugten, J., Somogyi, A., Nation, R., & Reynolds, G. (1997). The effect of old age on the disposition and antinociceptive response of morphine and morphine-6beta-glucuronide in the rat.. Pain, 71(2), 199-205. Scopus34 WoS31 Europe PMC26 |
| 1997 | Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1997). Influence of renal failure on the disposition of morphine, morphine-3-glucuronide and morphine-6-glucuronide in sheep during intravenous infusion with morphine. Journal of Pharmacology and Experimental Therapeutics, 282(2), 779-786. Scopus25 WoS21 Europe PMC14 |
| 1997 | Van Crugten, J., Somogyi, A., Nation, R., & Reynolds, G. (1997). Concentration-effect relationships of morphine and morphine-6beta-glucuronide in the rat. Clinical and Experimental Pharmacology and Physiology, 24(5), 359-364. Scopus21 WoS21 Europe PMC18 |
| 1997 | Somogyi, A. (1997). Pethidine is inappropriate for migraine. Australian Prescriber, 20(3), 71. Scopus1 |
| 1996 | Somogyi, A., Reinhard, H., & Bochner, F. (1996). Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism.. British Journal of Clinical Pharmacology, 41(3), 175-179. Scopus21 WoS16 Europe PMC11 |
| 1996 | Maddocks, I., Somogyi, A., Abbott, F., Hayball, P., & Parker, D. (1996). Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. Journal of Pain and Symptom Management, 12(3), 182-189. Scopus167 WoS119 Europe PMC105 |
| 1996 | Somogyi, A., Rumrich, G., Fritsch, G., & Ullrich, K. (1996). Stereospecificity in contraluminal and luminal transporters of organic cations in the proximal tubule.. Journal of Pharmacology and Experimental Therapeutics, 278(1), 31-36. Scopus16 WoS13 Europe PMC9 |
| 1996 | Somogyi, A., Reinhard, H., & Bochner, F. (1996). Effect of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in volunteers.. European Journal of Clinical Pharmacology, 50(5), 417-419. Scopus4 WoS4 Europe PMC3 |
| 1996 | Milne, R., Nation, R., & Somogyi, A. (1996). The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine.. Drug Metabolism Reviews, 28(3), 345-472. Scopus198 WoS180 Europe PMC136 |
| 1996 | Capon, D., Bochner, F., Kerry, N., Mikus, G., Danz, C., & Somogyi, A. (1996). The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.. Clinical Pharmacology and Therapeutics, 60(3), 295-307. Scopus128 WoS120 Europe PMC93 |
| 1996 | Kirkwood, L., Nation, R., Reynolds, G., Somogyi, A., & Sansom, L. (1996). Oxidative metabolism of dihydrocodeine in Dark- Agouti and Sprague-Dawley rat liver microsomes. Pharmaceutical Sciences, 2(6), 299-303. Scopus2 |
| 1996 | Somogyi, A. (1996). The new antidepressants. Australian Prescriber, 19(3), 60. |
| 1995 | KIRKWOOD, L. C., VENNING, M. G., NATION, R. L., REYNOLDS, G. D., SOMOGYI, A. A., & SANSOM, L. N. (1995). Comparative Activity of Dihydrocodeine and Its Metabolites in the Electrically Stimulated Guinea‐pig Isolated Ileum. Pharmacy and Pharmacology Communications, 1(12), 573-575. Scopus6 |
| 1995 | Somogyi, A., Bochner, F., Hetzel, D., & Williams, D. (1995). Evaluation of the intestinal absorption of erythromycin in man: Absolute bioavailability and comparison with enteric coated erythromycin. Pharmaceutical Research, 12(1), 149-154. Scopus23 WoS23 Europe PMC16 |
| 1995 | Milne, R., McLean, C., Mather, L., Nation, R., Runciman, W., Rutten, A., & Somogyi, A. (1995). Comparative disposition of morphine-3-glucuronide during separate intravenous infusions of morphine and morphine-3-glucuronide in sheep: Importance of the kidney. Drug Metabolism and Disposition, 23(3), 334-342. Scopus10 WoS8 Europe PMC5 |
| 1994 | Cleary, J. F., Mikus, G., Somogyi, A., & Bochner, F. (1994). The influence of pharmacogenetics on opioid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley/dark agouti rat model. Journal of Pharmacology and Experimental Therapeutics, 271(3), 1528-1534. Scopus72 WoS64 Europe PMC46 |
| 1994 | Douglas, A. M., Atchison, B. A., Somogyi, A. A., & Drummer, O. H. (1994). Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics, 4(3), 154-158. Scopus27 WoS26 Europe PMC11 |
| 1994 | Kerry, N., Somogyi, A., Bochner, F., & Mikus, G. (1994). The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.. British Journal of Clinical Pharmacology, 38(3), 243-248. Scopus104 WoS91 Europe PMC69 |
| 1994 | BOCHNER, F., MARTIN, E. D., BURGESS, N. G., SOMOGYI, A. A., MISAN, G. M. H., ANTIC, R., . . . YEOH, E. (1994). CONTROVERSIES IN TREATMENT - HOW CAN HOSPITALS RATION DRUGS - RESPONSE. BRITISH MEDICAL JOURNAL, 308(6933), 907-908. WoS1 |
| 1994 | Mikus, G., Bochner, F., Eichelbaum, M., Horak, P., Somogyi, A. A., & Spector, S. (1994). Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. Journal of Pharmacology and Experimental Therapeutics, 268(2), 546-551. Scopus48 WoS43 Europe PMC28 |
| 1994 | Bochner, F., Martin, E. D., Burgess, N. G., Somogyi, A. A., Misan, G. M. H., Donaldson, C., . . . Chadwick, R. (1994). Drug rationing in a teaching hospital: A method to assign priorities. British Medical Journal, 308(6933), 901-908. Scopus13 WoS34 |
| 1994 | Bochner, F., Martin, E. D., Burgess, N. G., Somogyi, A. A., & Misan, G. M. H. (1994). Controversies in Treatment: How can hospitals ration drugs? Drug rationing in a teaching hospital: A method to assign priorities. BMJ, 308(6933), 901. Scopus41 |
| 1994 | Bochner, F., Somogyi, A. A., & Chen, Z. R. (1994). Dextromethorphan metabolism in rat: Interstrain differences and the fate of individually administered oxidative metabolites. Xenobiotica, 24(6), 543-552. Scopus20 WoS14 Europe PMC9 |
| 1994 | SOMOGYI, A. A., SIMMONS, N., & GROSS, A. S. (1994). In‐vitro potencies of histamine H2‐receptor antagonists on tetraethylammonium uptake in rat renal brush‐border membrane vesicles. Journal of Pharmacy and Pharmacology, 46(5), 375-377. Scopus7 WoS7 Europe PMC6 |
| 1994 | Bochner, F., Martin, E. D., Burgess, N. G., Somogyi, A. A., & Misan, G. M. (1994). How can hospitals ration drugs? Drug rationing in a teaching hospital: a method to assign priorities. Drug Committee of the Royal Adelaide Hospital.. BMJ (Clinical research ed.), 308(6933), 901-905. Europe PMC22 |
| 1994 | Gross, A. S., & Somogyi, A. A. (1994). Interaction of the stereoisomers of basic drugs with the uptake of tetraethylammonium by rat renal brush-border membrane vesicles. Journal of Pharmacology and Experimental Therapeutics, 268(3), 1073-1080. Scopus19 WoS13 Europe PMC9 |
| 1993 | Somogyi, A. A., Nation, R. L., Olweny, C., Tsirgiotis, P., van Crugten, J., Milne, R. W., . . . Bochner, F. (1993). Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clinical Pharmacokinetics, 24(5), 413-420. Scopus48 WoS48 Europe PMC34 |
| 1993 | Milne, R. W., Sloan, P. A., McLean, C. F., Mather, L. E., Nation, R. L., Runciman, W. B., . . . Somogyi, A. A. (1993). Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. Drug metabolism and disposition, 21(6), 1151-1156. Scopus23 WoS21 Europe PMC14 |
| 1993 | Kerry, N. L., Somogyi, A. A., Mikus, G., & Bochner, F. (1993). Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female sprague-dawley and dark agouti rat liver microsomes. Biochemical Pharmacology, 45(4), 833-839. Scopus45 WoS44 Europe PMC28 |
| 1992 | Milne, R. W., Nation, R. L., Somogyi, A. A., Bochner, F., & Griggs, W. M. (1992). The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. British Journal of Clinical Pharmacology, 34(1), 53-59. Scopus81 WoS72 Europe PMC54 |
| 1992 | Somogyi, A. A., Bochner, F., & Sallustio, B. C. (1992). Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clinical Pharmacology and Therapeutics, 51(4), 379-387. Scopus45 WoS47 Europe PMC31 |
| 1991 | Bochner, F., Somogyi, A. A., & Wilson, K. M. (1991). Bioinequivalence of Four 100mg Oral Aspirin Formulations in Healthy Volunteers. Clinical Pharmacokinetics, 21(5), 394-399. Scopus31 WoS31 Europe PMC19 |
| 1991 | Mikus, G., Somogyi, A. A., Bochner, F., & Eichelbaum, M. (1991). Thebaine o-demethylation to oripavine: Genetic differences between two rat strains. Xenobiotica, 21(11), 1501-1509. Scopus28 WoS27 Europe PMC15 |
| 1991 | Milne, R. W., Nation, R. L., Reynolds, G. D., Somogyi, A. A., & van Crugten, J. T. (1991). High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies.. Journal of Chromatography B: Biomedical Applications, 565(1-2), 457-464. Scopus93 WoS87 Europe PMC45 |
| 1991 | Mikus, G., Somogyi, A. A., Bochner, F., & Elchelbaum, M. (1991). Codeine o-demethylation: Rat strain differences and the effects of inhibitors. Biochemical Pharmacology, 41(5), 757-762. Scopus48 WoS43 Europe PMC28 |
| 1991 | Mikus, G., Somogyi, A. A., Bochner, F., & Chen, Z. R. (1991). Polymorphic metabolism of opioid narcotic drugs: possible clinical implications. Annals of the Academy of Medicine Singapore, 20(1), 9-12. Scopus21 Europe PMC12 |
| 1991 | Chen, Z. R., Irvine, R. J., Somogyi, A. A., & Bochner, F. (1991). Mu receptor binding of some commonly used opioids and their metabolites. Life Sciences, 48(22), 2165-2171. Scopus256 WoS231 Europe PMC190 |
| 1991 | Chen, Z., Somogyi, A., Reynolds, G., & Bochner, F. (1991). Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.. British Journal of Clinical Pharmacology, 31(4), 381-390. Scopus140 WoS111 Europe PMC81 |
| 1991 | Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1991). Effect of racemic ibuprofen dose on the magnitude and duration of platelet cyclo-oxygenase inhibition: relationship between inhibition of thromboxane production and the plasma unbound concentration of S(+)-ibuprofen.. British journal of clinical pharmacology, 31(2), 131-138. Scopus52 WoS56 Europe PMC36 |
| 1991 | Sloan, P. A., Mather, L. E., Mclean, C. F., Rutten, A. J., Nation, R. L., Milne, R. W., . . . Somogyi, A. A. (1991). Physiological disposition of I.V. morphine in sheep. British Journal of Anaesthesia, 67(4), 378-386. Scopus25 WoS26 Europe PMC9 |
| 1991 | Van Crugten, J. T., Sallustio, B. C., Nation, R. L., & Somogyi, A. A. (1991). Renal tubular transport of morphine, morphine-6-glucuronide, and morphine-3-glucuronide in the isolated perfused rat kidney. Drug Metabolism and Disposition, 19(6), 1087-1092. Scopus43 WoS41 Europe PMC23 |
| 1991 | Muirhead, M. R., & Somogyi, A. A. (1991). Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney. Drug Metabolism and Disposition, 19(2), 312-316. Scopus15 WoS12 Europe PMC11 |
| 1991 | Somogyi, A., Bochner, F., & Chen, Z. R. (1991). Lack of effect of paracetamol on the pharmacokinetics and metabolism of codeine in man. European Journal of Clinical Pharmacology, 41(4), 379-382. Scopus14 WoS13 Europe PMC6 |
| 1990 | Somogyi, A., Siebert, D., & Bochner, F. (1990). Determination of endogenous concentrations of N1-methylnicotinamide in human plasma and urine by high-performance liquid chromatography. Analytical Biochemistry, 187(1), 160-165. Scopus19 WoS19 Europe PMC17 |
| 1990 | Chen, Z. R., Somogyi, A., & Bochner, F. (1990). Dextromethorphan: pharmacogenetics, and a pilot study to determine its disposition and antitussive effect in poor and extensive metabolisers. European Journal of Pharmacology, 183(4), 1573-1574. Scopus4 WoS2 |
| 1990 | Somogyi, A., Sallustio, B., & Bochner, F. (1990). Stereoselective reduction of pindolol enantiomer renal clearance by cimetidine in man. European Journal of Pharmacology, 183(4), 1157-1158. |
| 1990 | Zhao Rong Chen., Irvine, R. J., Bochner, F., & Somogyi, A. A. (1990). Morphine formation from codeine in rat brain: A possible mechanism of codeine analgesia. Life Sciences, 46(15), 1067-1074. Scopus70 WoS64 Europe PMC47 |
| 1990 | Wilson, K. M., Siebert, D. M., Duncan, E. M., Somogyi, A. A., Lloyd, J. V., & Bochner, F. (1990). Effect of aspirin infusions on platelet function in humans. Clinical Science, 79(1), 37-42. Scopus9 WoS11 Europe PMC7 |
| 1990 | Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1990). The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharmaceutics Drug Disposition, 11(6), 507-518. Scopus46 WoS49 Europe PMC29 |
| 1990 | Chen, Z. R., Somogyi, A. A., & Bochner, F. (1990). Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Therapeutic Drug Monitoring, 12(1), 97-104. Scopus129 WoS127 Europe PMC81 |
| 1990 | Misan, G. M. H., Martin, E. D., Smith, E. R., Somogyi, A. A., Bartholomeusz, R. C. A., & Bochner, F. (1990). Drug utilization review in a teaching hospital: experience with vancomycin. European Journal of Clinical Pharmacology, 39(5), 457-461. Scopus25 WoS25 Europe PMC18 |
| 1990 | SOMOGYI, A. A., WATSONABADY, J. A., & MANDEL, F. S. (1990). ATTITUDES TOWARD THE CARE OF PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME - A SURVEY OF COMMUNITY INTERNISTS. ARCHIVES OF INTERNAL MEDICINE, 150(1), 50-53. WoS9 |
| 1990 | Somogyi, A., Hewson, D., Muirhead, M., & Bochner, F. (1990). Amiloride disposition in geriatric patients: importance of renal function.. British Journal of Clinical Pharmacology, 29(1), 1-8. Scopus24 WoS19 Europe PMC15 |
| 1989 | CHEN, Z. R., REYNOLDS, G., BOCHNER, F., & SOMOGYI, A. (1989). DIRECT DETERMINATION OF CODEINE-6-GLUCURONIDE IN PLASMA AND URINE USING SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 493(2), 313-324. WoS19 |
| 1989 | Muirhead, M. R., Somogyi, A. A., Lloyd, C., & Bochner, F. (1989). Deconjugation of p-hydroxytriamterene sulphate in the rat. Xenobiotica, 19(6), 655-660. Scopus5 WoS3 Europe PMC4 |
| 1989 | Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1989). Stereoselective plasma protein binding of ibuprofen enantiomers. European journal of clinical pharmacology, 36(3), 283-290. Scopus93 WoS91 Europe PMC68 |
| 1989 | Somogyi, A. A., Hovens, C. M., Muirhead, M. R., & Bochner, F. (1989). Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model. Drug Metabolism and Disposition, 17(2), 190-196. Scopus36 WoS35 Europe PMC17 |
| 1989 | Chen, Z. R., Bochner, F., & Somogyi, A. (1989). Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications, 491(C), 367-378. Scopus39 WoS34 Europe PMC22 |
| 1989 | Rong Chen, Z., Reynolds, G., Bochner, F., & Somogyi, A. (1989). Direct determination of codeine-6-glucuronide in plasma and urine using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications, 493(C), 313-324. Scopus21 Europe PMC10 |
| 1988 | Chen, Z., Bochner, F., & Somogyi, A. (1988). Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies.. British Journal of Clinical Pharmacology, 26(4), 445-453. Scopus42 WoS27 Europe PMC15 |
| 1988 | Somogyi, A., Keal, J., & Bochner, F. (1988). Sensitive high-performance liquid chromatographic assay for determination of amiloride in biologic fluids using an ion-pair extraction method. Therapeutic Drug Monitoring, 10(4), 463-468. Scopus12 WoS11 Europe PMC6 |
| 1988 | Muirhead, M., Bochner, F., & Somogyi, A. (1988). Pharmacokinetic drug interactions between triamterene and ranitidine in humans: Alterations in renal and hepatic clearances and gastrointestinal absorption. Journal of Pharmacology and Experimental Therapeutics, 244(2), 734-739. Scopus37 WoS39 Europe PMC25 |
| 1988 | Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A. (1988). Stereoselective drug disposition: potential for misinterpretation of drug disposition data. British journal of clinical pharmacology, 26(6), 771-780. Scopus58 WoS53 Europe PMC47 |
| 1988 | Chen, Z. R., Siebert, D. M., Somogyi, A. A., & Bochner, F. (1988). Determination of pholcodine in biological fluids by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications, 424(C), 170-176. Scopus14 WoS12 Europe PMC8 |
| 1988 | Somogyi, A. A., & Bochner, F. (1988). The absorption and disposition of enoxacin in healthy subjects. Journal of Clinical Pharmacology, 28(8), 707-713. Scopus14 WoS12 Europe PMC11 |
| 1988 | Chen, Z. R., Somogyi, A. A., & Bochner, F. (1988). POLYMORPHIC O-DEMETHYLATION OF CODEINE. Lancet, 332(8616), 914-915. Scopus110 WoS98 Europe PMC71 |
| 1987 | Somogyi, A. A., Bochner, F., Keal, J. A., Rolan, P. E., & Smith, M. (1987). Effect of food on enoxacin absorption. Antimicrobial Agents and Chemotherapy, 31(4), 638-639. Scopus25 WoS30 Europe PMC26 |
| 1987 | Somogyi, A. (1987). New insights into the renal secretion of drugs. Trends in Pharmacological Sciences, 8(9), 354-357. Scopus31 WoS52 |
| 1987 | Somogyi, A., Muirhead, M., Kirch, W., Ohnhaus, E. E., & Pabst, J. (1987). Interaction of cimetidine with bisoprolol. European Journal of Clinical Pharmacology, 33(1), 109-110. Scopus1 WoS1 |
| 1987 | Somogyi, A., & Muirhead, M. (1987). Pharmacokinetic Interactions of Cimetidine 1987. Clinical Pharmacokinetics, 12(5), 321-366. Scopus182 WoS196 Europe PMC125 |
| 1987 | Heinzow, B. G. J., Somogyi, A., & McLean, A. J. (1987). Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine and conscious dogs. Archives Internationales De Pharmacodynamie Et De Therapie, 286(1), 5-14. Scopus6 WoS6 Europe PMC3 |
| 1987 | Somogyi, A., Stockley, C., Keal, J., Rolan, P., & Bochner, F. (1987). Reduction of metformin renal tubular secretion by cimetidine in man.. British Journal of Clinical Pharmacology, 23(5), 545-551. Scopus278 WoS237 Europe PMC186 |
| 1986 | Rolan, P., & Somogyi, A. (1986). Prescribing for the patient with renal disease. Medical Journal of Australia, 145(5), 210-215. WoS1 |
| 1986 | Keal, J., & Somogyi, A. (1986). Rapid and sensitive high-performance liquid chromatographic assay for metformin in plasma and urine using ion-pair extraction techniques. Journal of Chromatography B Biomedical Sciences and Applications, 378(C), 503-508. Scopus50 WoS47 Europe PMC18 |
| 1986 | Somogyi, A., & Rolan, P. (1986). Drug disposition and dosing in hepatic disease. Medical Journal of Australia, 145(6), 284-289. Scopus1 WoS2 Europe PMC1 |
| 1986 | Stockley, C., Keal, J., Rolan, P., Bochner, F., & Somogyi, A. (1986). Lack of inhibition of tolbutamide hydroxylation by cimetidine in man. European Journal of Clinical Pharmacology, 31(2), 235-237. Scopus16 WoS17 Europe PMC10 |
| 1986 | Van Crugten, J., Bochner, F., Keal, J., & Somogyi, A. (1986). Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. Journal of Pharmacology and Experimental Therapeutics, 236(2), 481-487. Scopus83 WoS80 Europe PMC43 |
| 1986 | Keal, J., Stockley, C., & Somogyi, A. (1986). Simultaneous determination of tolbutamide and its hydroxy and carboxy metabolites in plasma and urine by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications, 378(C), 237-241. Scopus14 WoS14 Europe PMC7 |
| 1986 | MARLIN, G. E., BRAUDE, P. D., WHELAN, A. J., & SOMOGYI, A. A. (1986). DISTRIBUTION OF ENOXACIN BETWEEN PLASMA AND BRONCHIAL-MUCOSA. AMERICAN REVIEW OF RESPIRATORY DISEASE, 133(4), A70. |
| 1986 | Marlin, G. E., Braude, P. D., Whelan, A. J., & Somogyi, A. A. (1986). Penetration of enoxacin into human bronchial mucosa. American Review of Respiratory Disease, 134(6), 1209-1212. Scopus25 WoS29 Europe PMC16 |
| 1986 | Muirhead, M. K., somogyi, A. A., Rolan, P. E., & Bochner, F. (1986). Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene. Clinical Pharmacology and Therapeutics, 40(4), 400-407. Scopus44 WoS54 Europe PMC30 |
| 1985 | Somogyi, A., Becker, M., & Gugler, R. (1985). Cimetidine pharmacokinetics and dosage requirements in children. European Journal of Pediatrics, 144(1), 72-76. Scopus29 WoS21 Europe PMC17 |
| 1985 | Somogyi, A., & Gugler, R. (1985). Effect of variations in urine pH and flow rate on cimetidine renal disposition in man. Biopharmaceutics Drug Disposition, 6(3), 345-349. Scopus4 WoS5 Europe PMC2 |
| 1985 | Somogyi, A., & Bochner, F. (1985). Ranitidine and procainamide absorption [letter]. British Journal of Clinical Pharmacology, 20(2), 182-183. Scopus3 WoS2 Europe PMC3 |
| 1985 | Gugler, R., Jensen, J. C., Rohner, H. G., Reimnitz, P., & Somogyi, A. (1985). Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klinische Wochenschrift, 63(22), 1152-1159. Scopus8 WoS13 Europe PMC5 |
| 1984 | Somogyi, A., & Bochner, F. (1984). Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man.. British Journal of Clinical Pharmacology, 18(2), 175-181. Scopus68 WoS64 Europe PMC45 |
| 1984 | Eichelbaum, M., & Somogyi, A. (1984). Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing - Studies with deuterated verapamil. European Journal of Clinical Pharmacology, 26(1), 47-53. Scopus51 WoS69 Europe PMC38 |
| 1984 | Somogyi, A. A., Kong, C. B., Gurr, F. W., Sabto, J., Spicer, W. J., & Mclean, A. J. (1984). Metronidazole pharmacokinetics in patients with acute renal failure. Journal of Antimicrobial Chemotherapy, 13(2), 183-189. Scopus19 WoS9 Europe PMC7 |
| 1983 | Somogyi, A., McLean, A., & Heinzow, B. (1983). Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs. European Journal of Clinical Pharmacology, 25(3), 339-345. Scopus153 WoS151 Europe PMC95 |
| 1983 | Somogyi, A., & Gugler, R. (1983). Clinical Pharmacokinetics of Cimetidine. Clinical Pharmacokinetics, 8(6), 463-495. Scopus151 WoS166 Europe PMC108 |
| 1983 | Somogyi, A., Kong, C., Sabto, J., Gurr, F. W., Spicer, W. J., & McLean, A. J. (1983). Disposition and removal of metronidazole in patients undergoing haemodialysis. European Journal of Clinical Pharmacology, 25(5), 683-687. Scopus11 WoS9 Europe PMC7 |
| 1983 | Mclean, A., Somogyi, A., Ioannides-Demos, L., Tong, N., & Spicer, J. (1983). SUCCESSFUL SUBSTITUTION OF RECTAL METRONIDAZOLE ADMINISTRATION FOR INTRAVENOUS USE. Lancet, 321(8314-8315), 41-43. Scopus9 WoS13 Europe PMC8 |
| 1983 | Rolan, P. E., Somogyi, A. A., Drew, M. J. R., Cobain, W. G., South, D., & Bochner, F. (1983). Phenytoin intoxication during treatment with parenteral miconazole. British Medical Journal, 287(6407), 1760. Scopus26 WoS24 Europe PMC18 |
| 1983 | Ioannides Demos, L. L., Tong, N., & Somogyi, A. A. (1983). Clinical pharmacy monitoring and utilisation of enteral and parenteral metronidazole in a general hospital. Australian Journal of Hospital Pharmacy, 13(1), 4-7. Scopus1 |
| 1983 | Morgan, D. J., Ching, M. S., Raymond, K., Bury, R. W., Mashford, M. L., Kong, B., . . . Somogyi, A. A. (1983). Elimination of amphotericin B in impaired renal function. Clinical Pharmacology and Therapeutics, 34(2), 248-253. Scopus27 WoS26 Europe PMC19 |
| 1982 | Somogyi, A., & Heinzow, B. (1982). Cimetidine Reduces Procainamide Elimination. New England Journal of Medicine, 307(17), 1080. Scopus26 WoS30 Europe PMC15 |
| 1982 | Gugler, R., Rohner, H. G., & Somogyi, A. A. (1982). Treatment failure of cimetidine in duodenal ulcer. Deutsche Medizinische Wochenschrift, 107(27), 1054-1057. Scopus7 WoS12 Europe PMC7 |
| 1982 | EICHELBAUM, M., OCHS, H. R., ROBERTS, G., & SOMOGYI, A. (1982). PHARMACOKINETICS AND METABOLISM OF ANTIPYRINE (PHENAZONE) AFTER INTRAVENOUS AND ORAL-ADMINISTRATION. ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 32-1(5), 575-578. WoS44 |
| 1982 | Gugler, R., Muller‐Liebenau, B., & Somogyi, A. (1982). Altered disposition and availability of cimetidine in liver cirrhotic patients.. British Journal of Clinical Pharmacology, 14(3), 421-430. Scopus16 WoS17 Europe PMC15 |
| 1982 | Somogyi, A., Gugler, R., & Muller Liebenau, B. (1982). Influence of liver cirrhosis on the pharmacokinetics, bioavailability and metabolism of cimetidine. Clinical and Experimental Pharmacology and Physiology, 9(4), 400. |
| 1982 | Eichelbaum, M., Ochs, H. R., Roberts, G., & somogyi, A. (1982). Pharmacokinetics and metabolism of antipyrine (Phenazone) after intravenous and oral administration. Arzneimittel Forschung Drug Research, 32(5), 575-578. Scopus41 Europe PMC19 |
| 1982 | KUSZYNSKI, C., SOMOGYI, A., & LANGENBACH, R. (1982). MODIFICATION OF BENZO[ALPHA]PYRENE-INDUCED TRANSFORMATION OF C3H-10T1/2 CELLS BY PREGNENOLONE-16-ALPHA-CARBONITRILE AND DEXAMETHASONE. CANCER LETTERS, 15(3), 215-221. WoS3 |
| 1982 | Somogyi, A., & Gugler, R. (1982). Drug Interactions with Cimetidine. Clinical Pharmacokinetics, 7(1), 23-41. Scopus223 WoS291 Europe PMC179 |
| 1982 | Somogyi, A., Eichelbaum, M., & Gugler, R. (1982). Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. European Journal of Clinical Pharmacology, 22(1), 85-90. Scopus17 WoS19 Europe PMC10 |
| 1982 | Gugler, R., Rohner, H. G., & Somogyi, A. A. (1982). Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clinical Pharmacology and Therapeutics, 31(4), 501-507. Scopus3 WoS12 Europe PMC3 |
| 1982 | Eichelbaum, M., von Unruh, G. E., & Somogyi, A. (1982). Application of Stable Labelled Drugs in Clinical Pharmacokinetic Investigations. Clinical Pharmacokinetics, 7(6), 490-507. Scopus56 WoS50 Europe PMC36 |
| 1981 | Ramzan, M. I., Somogyi, A. A., Walker, J. S., Shanks, C. A., & Triggs, E. J. (1981). Clinical Pharmacokinetics of the Non-depolarising Muscle Relaxants. Clinical Pharmacokinetics, 6(1), 25-60. Scopus22 WoS20 Europe PMC9 |
| 1981 | Gugler, R., Fuchs, G., Dieckmann, M., & Somogyi, A. A. (1981). Cimetidine plasma concentration-response relationships. Clinical Pharmacology and Therapeutics, 29(6), 744-748. Scopus42 WoS56 Europe PMC39 |
| 1981 | Eichelbaum, M., Somogyi, A., von Unruh, G. E., & Dengler, H. J. (1981). Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. European Journal of Clinical Pharmacology, 19(2), 133-137. Scopus100 WoS113 Europe PMC70 |
| 1981 | Gugler, R., Brand, M., & Somogyi, A. (1981). Impaired cimetidine absorption due to antacids and metoclopramide. European Journal of Clinical Pharmacology, 20(3), 225-228. Scopus58 WoS71 Europe PMC49 |
| 1981 | Somogyi, A., Thielscher, S., & Gugler, R. (1981). Influence of phenobarbital treatment on cimetidine kinetics. European Journal of Clinical Pharmacology, 19(5), 343-347. Scopus25 WoS25 Europe PMC19 |
| 1981 | Eichelbaum, M., Dengler, H. J., Somogyi, A., & von Unruh, G. E. (1981). Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination - Studies of the relative bioavailability of verapamil tablets. European Journal of Clinical Pharmacology, 19(2), 127-131. Scopus67 WoS76 Europe PMC43 |
| 1981 | KUSZYNSKI, C., SOMOGYI, A., NESNOW, S., & LANGENBACH, R. (1981). INHIBITION OF BENZO(A)PYRENE-INDUCED TRANSFORMATION OF C3H-1OT1-2 CELLS BY ALLYLISOPROPYLACETAMIDE AND ISOPROPYLVALERAMIDE. CANCER RESEARCH, 41(5), 1893-1897. WoS8 |
| 1981 | Ioannides, L., Somogyi, A., Spicer, J., Heinzow, B., Tong, N., Franklin, C., & Mclean, A. (1981). Rectal Administration of Metronidazole Provides Therapeutic Plasma Levels in Postoperative Patients. New England Journal of Medicine, 305(26), 1569-1570. Scopus31 WoS40 Europe PMC27 |
| 1981 | Eichelbaum, M., & Somogyi, A. (1981). Pharmacokinetics and bioavailability of verapamil during chronic oral dosage. Naunyn Schmiedeberg S Archives of Pharmacology, 316(Suppl.), 292. Scopus2 |
| 1981 | Somogyi, A., & Gugler, R. (1981). Clinical pharmacokinetics of cimetidine with observations on the plasma concentration-response curve. Methods and Findings in Experimental and Clinical Pharmacology, 3(Suppl. 1), S83-S87. Scopus6 WoS4 Europe PMC4 |
| 1981 | Somogyi, A., Albrecht, M., Kliems, G., Schafer, K., & Eichelbaum, M. (1981). Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.. British Journal of Clinical Pharmacology, 12(1), 51-60. Scopus108 WoS119 Europe PMC75 |
| 1981 | Gugler, R., Somogyi, A., & Bergmann, K. (1981). The biliary excretion of histamine H2-receptor antagonists cimetidine and oxmetidine. Clinical Pharmacology and Therapeutics, 29(2), 249-250. Scopus14 WoS19 |
| 1980 | Eichelbaum, M., Albrecht, M., Kliems, G., Schafer, K., & Somogyi, A. (1980). Influence of meso‐caval shunt surgery on verapamil kinetics, bioavailability and response.. British Journal of Clinical Pharmacology, 10(5), 527-530. Scopus28 WoS35 Europe PMC22 |
| 1980 | Shanks, C. A., Somogyi, A. A., Ramzan, M. I., & Triggs, E. J. (1980). Tubocurarine and pancuronium: A pharmacokinetic view. Anaesthesia and Intensive Care, 8(1), 4-12. Scopus1 WoS5 Europe PMC1 |
| 1980 | Somogyi, A. (1980). Pancuronium plasma clearance and age. British Journal of Anaesthesia, 52(3), 360. WoS4 Europe PMC1 |
| 1980 | Somogyi, A., & Gugler, R. (1980). Absolute bioavailability of theophylline. Fortschritte Der Medizin, 98(43), 1707-1710. Scopus1 WoS4 Europe PMC1 |
| 1980 | Somogyi, A. A., & Gugler, R. (1980). Gastric acid inhibitory effect and pharmacokinetics of a new histamine-H2-antagonist, 92 994. Hepato Gastroenterology, 27(SUPPL.), E32.13. |
| 1980 | Gugler, R., Wolf, H., Kliems, G., & Somogyi, A. (1980). Bioavailability of cimetidine after partial gastrectomy. Munchener Medizinische Wochenschrift, 122(39), 1337-1340. Scopus4 WoS4 Europe PMC3 |
| 1980 | Somogyi, A., Rohner, H. G., & Gugler, R. (1980). Pharmacokinetics and Bioavailability of Cimetidine in Gastric and Duodenal Ulcer Patients. Clinical Pharmacokinetics, 5(1), 84-94. Scopus80 WoS108 Europe PMC62 |
| 1980 | Eichelbaum, M., Birkel, P., Grube, E., Gütgemann, U., & Somogyi, A. (1980). Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment. Klinische Wochenschrift, 58(18), 919-925. Scopus88 WoS128 Europe PMC66 |
| 1979 | Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1979). Dose-response and plasma concentration-response relationships of pancuronium in man. Anesthesiology, 51(2), 111-118. Scopus19 WoS53 Europe PMC17 |
| 1979 | Gugler, R., Djowinarto, H., Kliems, G., & Somogyi, A. A. (1979). Cimetidine kinetics in patients after Billroth I and II gastric resections. Zeitschrift Fur Gastroenterologie, 17(9), 640-641. |
| 1979 | Gugler, R., & Somogyi, A. (1979). Reduced Cimetidine Clearance with Age. New England Journal of Medicine, 301(8), 435. Scopus7 Europe PMC5 |
| 1979 | Somogyi, A., & Gugler, R. (1979). Cimetidine excretion into breast milk.. British Journal of Clinical Pharmacology, 7(6), 627-629. Scopus73 WoS69 Europe PMC45 |
| 1979 | Somogyi, A., Gugler, R., Redolfi, A., Borgogelli, E., & Lodola, E. (1979). Increased bioavailability of cimetidine with age? - Letter to the editor concerning the article "blood level of cimetidine in relation to age" by A. Redolfi, E. Borgogelli, and E. Lodola Eur. J. Clin. Pharmacol. 15, 257-261 (1979). European Journal of Clinical Pharmacology, 16(6), 431-433. Scopus1 WoS4 Europe PMC4 |
| 1978 | Shanks, C., Somogyi, A., & Triggs, E. (1978). Plasma levels of pancuronium as a determinant of neuromuscular response in man [proceedings]. British Journal of Clinical Pharmacology, 6(5), 452-453. |
| 1978 | Somogyi, A. A., Triggs, E. J., & Shanks, C. A. (1978). Pancuronium disposition and response. Clinical and Experimental Pharmacology and Physiology, 5(3), 250. WoS2 |
| 1978 | Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1978). Combined I.V. Bolus and infusion of pancuronium bromide. British Journal of Anaesthesia, 50(6), 575-582. Scopus10 WoS19 Europe PMC7 |
| 1978 | Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1978). Plasma concentrations of pancuronium during predetermined intensities of neuromuscular blockade. British Journal of Anaesthesia, 50(3), 235-239. Scopus8 WoS15 Europe PMC6 |
| 1977 | Somogyi, A. A., Triggs, E. J., & Shanks, C. A. (1977). Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. British Journal of Anaesthesia, 49(11), 1103-1108. Scopus31 WoS65 Europe PMC22 |
| 1977 | Shanks, C. A., Somogyi, A. A., & Triggs, E. J. (1977). Plasma pancuronium concentrations during predetermined intensities of neuromuscular blockade. Anaesthesia and Intensive Care, 5(4), 395. |
| 1977 | Shanks, C., Somogyi, A., & Triggs, E. (1977). Neuromuscular responses and blood concentrations of pancuronium. Anaesthesia and Intensive Care, 5(1), 81. |
| 1977 | Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1977). The effect of renal failure on the disposition and neuromuscular blocking action of pancuronium bromide. European Journal of Clinical Pharmacology, 12(1), 23-29. Scopus32 WoS46 Europe PMC20 |
| 1976 | Somogyi, A. A., Shanks, C. A., & Triggs, E. J. (1976). Clinical pharmacokinetics of pancuronium bromide. European Journal of Clinical Pharmacology, 10(5), 367-372. Scopus19 WoS47 Europe PMC17 |
| 1976 | SOMOGYI, A., MALICK, L. E., LANGENBACH, R., & SALLACH, K. (1976). CONTEMPORARY ANIMAL NUTRITION AND ITS POTENTIAL HAZARDS TO HUMAN HEALTH. ZENTRALBLATT FUR BAKTERIOLOGIE MIKROBIOLOGIE UND HYGIENE SERIE B-UMWELTHYGIENE KRANKENHAUSHYGIENE ARBEITSHYGIENE PRAVENTIVE MEDIZIN, 163(1-4), 153-172. |
| 1975 | SOMOGYI, A., LEVIN, W., BANERJEE, S., KUNTZMAN, R., & CONNEY, A. H. (1975). INHIBITION OF ACUTE TOXICITY AND ADRENOCORTICOLYTIC EFFECT OF 7,12-DIMETHYLBENZ(A)ANTHRACENE BY ISOPROPYLVALERAMIDE AND ALLYLISOPROPYLACETAMIDE IN RAT. CANCER RESEARCH, 35(9), 2500-2505. WoS5 |
| 1973 | CONNEY, A. H., LU, A. Y. H., LEVIN, W., SOMOGYI, A., WEST, S., JACOBSON, M., . . . KUNTZMAN, R. (1973). EFFECT OF ENZYME INDUCERS ON SUBSTRATE-SPECIFICITY OF CYTOCHROME P-450S. DRUG METABOLISM AND DISPOSITION, 1(1), 199-210. WoS61 |
| 1972 | LU, A. Y. H., WEST, S., SOMOGYI, A., CONNEY, A. H., & KUNTZMAN, R. (1972). PREGNENOLONE-16ALPHA-CARBONITRILE - NEW TYPE OF INDUCER OF DRUG-METABOLIZING ENZYMES. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 152(2), 457-&. WoS226 |
| 1971 | SOMOGYI, A., KOVACS, K., SOLYMOSS, B., KUNTZMAN, R., & CONNEY, A. H. (1971). SUPPRESSION OF 7,12-DIMETHYLBENZ[ALPHA]ANTHRACENE-PRODUCED ADRENAL NCROSIS BY STEROIDS CAPABLE OF INDUCING ARYL HYDROCARBON HYDROXYLASE. LIFE SCIENCES PT-2 BIOCHEMISTRY GENERAL AND MOLECULAR BIOLOGY, 10(22), 1261-&. WoS43 |
| 1970 | SOMOGYI, A., & KOVACS, K. (1970). DIMETHYL SULFOXIDE, A CONVENIENT SOLVENT OF 7,12-DIMETHYLBENZ(A)ANTHRACENE FOR INTRAVENOUS INJECTION. CANCER RESEARCH, 30(7), 1958-&. WoS11 |
| Year | Citation |
|---|---|
| 2016 | Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger. DOI |
| 2016 | Martin, J., & Somogyi, A. (2016). Issues of Pharmacogenomics in Monitoring Warfarin Therapy. In W. Clarke, & A. Dasgupta (Eds.), Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics (1 ed., pp. 261-277). Amsterdam, Netherlands: Elsevier. DOI |
| 2012 | Martin, J., & Somogyi, A. (2012). Pharmacogenomics and Warfarin Therapy. In Therapeutic Drug Monitoring Newer Drugs and Biomarkers (pp. 161-173). DOI Scopus1 |
| 2012 | Martin, J., & Somogyi, A. (2012). Pharmacogenomics and Warfarin therapy. In A. Dastupta (Ed.), Therapeutic Drug Monitoring: Newer Drugs and Biomarkers (1 ed., pp. 161-173). United States: Elsevier. DOI Scopus1 |
| 2012 | Somogyi, A., & Coller, J. (2012). Drugs against acute and chronic pain. In P. Anzenbacher, & U. Zanger (Eds.), Metabolism of Drugs and Other Xenobiotics (1 ed., pp. 403-428). Germany: Wiley. DOI Scopus4 |
| 2010 | Somogyi, A. (2010). Pharmacogenetics in palliative care. In W. Newman (Ed.), Pharmacogenetics: making Cancer treatment safer and more effective (pp. 115-125). Dordrecht: Springer. DOI |
| 2009 | Gordon, A., Hutchinson, M., La Vincente, S., Mitchell, T., Morrish, G., Newcombe, D., . . . White, J. (2009). Pharmacology of opioid agonists and antagonists. In R. Mattick, R. Ali, & N. Lintzeris (Eds.), Pharmacotherapies for the Treatment of Opioid Dependence: Efficacy, Cost-Effectiveness and Implementation Guidelines (pp. 15-53). New York, USA: Informa. |
| 2008 | Somogyi, A., & Coller, J. (2008). Pharmacogenomics and Pharmacogenetics. In An Integrated Compendium of Twenty Encyclopedias (pp. 1-20). United Kingdom: Eolss Publishers. |
| 2002 | Gross, A. S., Somogyi, A., & Eichelbaum, M. (2002). Stereoselective Drug Metabolism and Drug Interactions. In M. Eichelbaum, B. Testa, & A. Somogyi (Eds.), Handbook of Experimental Pharmacology (Vol. 153, pp. 313-339). |
| 2002 | Gross, A. S., Somogyi, A., & Eichelbaum, M. (2002). Stereoselective Drug Metabolism and Drug Interactions. In M. Eichelbaum, B. Testa, & A. Somogyi (Eds.), Handbook of Experimental Pharmacology (Vol. 153, pp. 313-339). |
| 1998 | Somogyi, A. A. (1998). Clinical pharmacokinetics and drug dosing. In T. M. Brody, J. Larner, K. P. Minneman, & H. C. Neu (Eds.), Human Pharmacology : Molecular to Clinical (3rd ed.). |
| 1996 | Somogyi, A. A. (1996). Drug interactions involving renal excretory mechanisms in Mechanisms of Drug Interactions. In F. F. D'Arcy, J. C. McElnay, & P. G. Welling (Eds.), Handbook of Experimental Pharmacology (Vol. 122, pp. 173-212). |
| 1982 | Somogyi, A. A., & Eichelbaum, M. (1982). Pharmacokinetics, bioavailability and ECG response of verapamil in man. In M. Kaltenbach, & S. E. Epstein (Eds.), Hypertrophic Cardiomyopathy (pp. 291). |
| 1980 | Somogyi, A. A. (1980). Disposition of non-depolarizing muscle relaxants. In C. Conseiller, J. M. Desmonts, P. Glaser, J. Montagne, G. G. Nahas, J. C. Salamagne, . . . G. Vourc'h (Eds.), Curares and Curarisation (pp. 197-207). |
| 1980 | Somogyi, A. A., & Gugler, R. (1980). Methods in Clinical Pharmacology. In N. Rietbrock, B. G. Woodcock, & G. Neuhaus (Eds.), Methods in Clinical Pharmacology (pp. 242-249). |
| Year | Citation |
|---|---|
| 2022 | Kisely, S., Connor, M., & Somogyi, A. (2022). DO PSILOCYBIN OR METHYLENEDIOXYME THAMPHETAMINE (MDMA) IMPROVE MENTAL, BEHAVIOURAL OR DEVELOPMENTAL DISORDERS EITHER AS STAND-ALONE TREATMENTS OR IN COMBINATION WITH PSYCHOTHERAPY?. In AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY Vol. 56 (pp. 179). SAGE PUBLICATIONS LTD. |
| 2021 | Figon, F., Hurbain, I., Heiligenstein, X., Trepout, S., Medjoubi, K., Somogyi, A., . . . Casas, J. (2021). Within-cell cycle of endolysosome-related pigment organelles in crab spiders leads to reversible color changes. In INTEGRATIVE AND COMPARATIVE BIOLOGY Vol. 61 (pp. E255). ELECTR NETWORK: OXFORD UNIV PRESS INC. |
| 2019 | Wang, D., Wu, J., Rowsell, L., Wong, K., Yee, B., Somogyi, A., & Grunstein, R. (2019). THE EFFECT OF MORPHINE ON SLEEP: IS THERE A GENETIC EFFECT? - AN RCT STUDY. In SLEEP MEDICINE Vol. 64 (pp. S409). ELSEVIER. |
| 2018 | Ilyas, F., Somogyi, A., & Gabb, G. (2018). THERAPEUTIC DRUG SAFETY, IMPORTANT TO 'CLOSE THE GAP' FOR ABORIGINAL AND TORRES STRAIT ISLANDERS: A CASE OF PHENYTOIN HYPERSENSITIVITY SYNDROME. In INTERNAL MEDICINE JOURNAL Vol. 48 (pp. 12). WILEY. |
| 2016 | Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia. |
| 2016 | Rowsell, L., Yee, B., Wong, K., Somogyi, A., Eckert, D., Grunstein, R., & Wang, D. (2016). THE PHARMACOGENOMICS OF MORPHINE EFFECT ON OBSTRUCTIVE SLEEP APNEA: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED CROSSOVER TRIAL. In JOURNAL OF SLEEP RESEARCH Vol. 25 (pp. 6-7). WILEY-BLACKWELL. |
| 2012 | Wang, D., Somogyi, A., Yee, B., Wong, K., Kaur, J., Wrigley, P., & Grunstein, R. (2012). The effects of morphine on chemoreflexes and breathing in obstructive sleep apnoea. In JOURNAL OF SLEEP RESEARCH Vol. 21 (pp. 63-64). Paris, FRANCE: WILEY-BLACKWELL. |
| 2011 | Wang, D., Somogyi, A., Yee, B., Wong, K., Singh, J., Wrigley, P., & Grunstein, R. (2011). Can minocycline reverse morphine-induced respiratory depression in obstructive sleep apnea patients?. In JOURNAL OF SLEEP RESEARCH Vol. 20 (pp. 62-63). Sydney, AUSTRALIA: WILEY-BLACKWELL. |
| 2011 | Wang, J., Hughes, T. P., Kok, C. H., Saunders, V. A., Frede, A., GrootObbink, K., . . . White, D. L. (2011). Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy. In BLOOD Vol. 118 (pp. 1493-1494). San Diego, CA: AMER SOC HEMATOLOGY. |
| 2011 | Sallustio, B. C., Noll, B., Coller, J., Somogyi, A., van Gelder, T., Hesselink, D., & Morris, R. G. (2011). LC-MS/MS quantification of tacrolimus concentrations in small samples of kidney and liver tissue. In THERAPEUTIC DRUG MONITORING Vol. 33 (pp. 540). Stuttgart, GERMANY: LIPPINCOTT WILLIAMS & WILKINS. |
| 2009 | Somogyi, A. A., Gelston, E., Coller, J. K., White, J. M., & Schmidt, H. (2009). Methadone Inhibits CYP2D6 and UGT2B7 <i>In Vivo</i>: a Study using Codeine as the Substrate. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 45-46). Lisbon, PORTUGAL: TAYLOR & FRANCIS INC. WoS1 |
| 2009 | Licari, J., Somogyi, A. A., Pierides, J., & Sallustio, B. C. (2009). Comparison of sprague dawley and dark agouti rats as animal models of perhexiline-induced hepatotoxicity. In DRUG METABOLISM REVIEWS Vol. 41 (pp. 128). Baltimore, MD: TAYLOR & FRANCIS INC. |
| 2007 | Sallustio, B. C., Davies, B. J., Herbert, M. K., Coller, J. K., Somogyi, A. A., & Milne, R. W. (2007). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 extensive and poor metabolisers. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 478). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS. |
| 2007 | Somogyi, A., Culler, J., Hallinan, R., & Foster, D. (2007). Pharmacokinetics and pharmacogenomics of high dose methadone in maintenance subjects. In THERAPEUTIC DRUG MONITORING Vol. 29 (pp. 485-486). Nice, FRANCE: LIPPINCOTT WILLIAMS & WILKINS. |
| 2006 | James, H., Gillis, D., Hissaria, P., Lester, S., Somogyi, A., Cleland, L., & Proudman, S. (2006). Polymorphisms in the folate pathway predict response to methotrexate in early RA.. In ARTHRITIS AND RHEUMATISM Vol. 54 (pp. S129). Washington, DC: WILEY-LISS. |
| 2006 | Somogyi, A., Nguyen, M., Lopatko, O., Foster, D., & White, J. (2006). Comparison of pharmacokinetics and pharmacodynamics of R-, S- and racemic-methadone in healthy subjects. In ACTA PHARMACOLOGICA SINICA Vol. 27 (pp. 418). BLACKWELL PUBLISHING. |
| 2005 | Morrish, G. A., Somogyi, A. A., & Foster, D. J. R. (2005). Population pharmacokinetic analysis of morphine in opioid dependent and control subjects. In DRUG METABOLISM REVIEWS Vol. 37 (pp. 60). Nice, FRANCE: TAYLOR & FRANCIS INC. |
| 2004 | Morton, E. B., Somogyi, A. A., Bochner, F., & White, J. M. (2004). The clinical pharmacology of methadone induction. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 31 (pp. A226-A227). Brisbane, AUSTRALIA: BLACKWELL PUBLISHING ASIA. |
| 2003 | Drescher, S., Glaeser, H., Hofmann, U., Somogyi, A. A., Eichelbaum, M., & Fromm, M. F. (2003). Rate of intraluminal drug delivery determines bioavailability of verapamil. In DRUG METABOLISM REVIEWS Vol. 35 (pp. 68). DIJON, FRANCE: MARCEL DEKKER INC. WoS2 |
| 2001 | Somogyi, A., Athanasos, P., White, J., & Bochner, F. (2001). Respiratory depression and methadone induction. In TOXICOLOGY Vol. 164 (pp. 42). ELSEVIER SCI IRELAND LTD. |
| 1996 | Somogyi, A. (1996). Renal transport of drugs: Specificity and molecular mechanisms. In Clinical and Experimental Pharmacology and Physiology Vol. 23 (pp. 986-989). ADELAIDE, AUSTRALIA: BLACKWELL SCIENCE. DOI Scopus42 WoS29 Europe PMC21 |
| 1990 | Bochner, F., Chen, Z. R., Young, G., Somogyi, A., & Reynolds, G. (1990). Codeine disposition and metabolism: Comparison in young and elderly subjects. In European Journal of Pharmacology Vol. 183 (pp. 630-631). ELSEVIER SCIENCE BV. DOI Scopus3 WoS3 |
| 1986 | BLAZOVICS, A., SOMOGYI, A., FEHER, E., TONCSEV, H., & FEHER, J. (1986). EFFECT OF DIHYDROQUINOLINE TYPE ANTIOXIDANTS ON HEPATIC-MICROSOMAL ENZYME-ACTIVITY AND LIPID-PEROXIDATION IN EXPERIMENTAL HYPERLIPOPROTEINEMIA. In DIGESTIVE DISEASES AND SCIENCES Vol. 31 (pp. S407). PLENUM PUBL CORP. |
| 1983 | GUGLER, R., MULLERLIEBENAU, B., & SOMOGYI, A. (1983). ALTERED DISPOSITION AND AVAILABILITY OF CIMETIDINE IN PATIENTS WITH LIVER-CIRRHOSIS. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 33 (pp. 217). MOSBY-YEAR BOOK INC. |
| 1983 | SOMOGYI, A., MCLEAN, A., & HEINZOW, B. (1983). INFLUENCE OF CIMETIDINE ON PROCAINAMIDE PHARMACOKINETICS IN MAN. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 720). BLACKWELL SCIENCE. |
| 1983 | CHING, M. S., MORGAN, D. J., RAYMOND, K., BURY, R. W., MASHFORD, M. L., GURR, F. W., & SOMOGYI, A. A. (1983). ELIMINATION OF AMPHOTERICIN-B IN PATIENTS WITH IMPAIRED RENAL-FUNCTION. In CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY Vol. 10 (pp. 646). BLACKWELL SCIENCE. |
| 1980 | SOMOGYI, A. A., ROHNER, H. G., & GUGLER, R. (1980). CIMETIDINE PHARMACOKINETICS IN ULCER PATIENTS. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 27 (pp. 287). MOSBY-YEAR BOOK INC. WoS1 |
| 1980 | GUGLER, R., DJOJOWINARTO, H., KLIEMS, G., & SOMOGYI, A. A. (1980). CIMETIDINE DISPOSITION IN PATIENTS WITH PARTIAL GASTRECTOMY. In CLINICAL PHARMACOLOGY & THERAPEUTICS Vol. 27 (pp. 256-257). MOSBY-YEAR BOOK INC. |
| 1979 | SOMOGYI, A. A., TRIGGS, E. J., & SHANKS, C. A. (1979). PHARMACOKINETICS AND DURATION OF ACTION OF PANCURONIUM IN PATIENTS WITH TOTAL BILIARY OBSTRUCTION. In NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY Vol. 307 (pp. R74). SPRINGER VERLAG. |
| 1979 | GUGLER, R., DJOWINARTO, H., KLIEMS, G., & SOMOGYI, A. A. (1979). KINETICS OF CIMETIDINE IN PATIENTS AFTER BILLROTH GASTRECTOMIES I AND II. In ZEITSCHRIFT FUR GASTROENTEROLOGIE Vol. 17 (pp. 640-641). DEMETER VERLAG. WoS1 |
| 1968 | SELYE, H., SOMOGYI, A., & VEGH, P. (1968). INFLAMMATION TOPICAL STRESS AND CONCEPT OF PLURICAUSAL DISEASES. In BIOCHEMICAL PHARMACOLOGY Vol. S (pp. 107-+). PERGAMON-ELSEVIER SCIENCE LTD. |
| Year | Citation |
|---|---|
| 2024 | Martin, D., Harvey, A., Baune, B., Berk, M., Carter, G., Dong, V., . . . Loo, C. (2024). Cognitive Outcomes Following a Course of Racemic Ketamine: Results From the Randomised, Active-Controlled Ketamine for Adult Depression Study (KADS). Poster session presented at the meeting of Abstracts of the 79th Annual Meeting of the Society of Biological Psychiatry (SOBP 2024) as published in Biological Psychiatry. Austin, Texas, USA: Elsevier. DOI |
| 2020 | Ferreira, D., Barratt, D., Somogyi, A., & Currow, D. (2020). Genetics of response to sustained-release morphine for chronic breathlessness - an exploratory study. Poster session presented at the meeting of EUROPEAN RESPIRATORY JOURNAL. ELECTR NETWORK: EUROPEAN RESPIRATORY SOC JOURNALS LTD. DOI |
| 2015 | Dom, Z. M., Coller, J., Carroll, R., Somogyi, A., & Sallustio, B. (2015). Intra-Lymphocyte Concentrations of Mycophenolic Acid Correlate With the Incidence of Early Graft Rejection in Renal Transplant Recipients. Poster session presented at the meeting of AMERICAN JOURNAL OF TRANSPLANTATION. Philadelphia, PA: WILEY-BLACKWELL. |
| 2015 | Somogyi, A. A. (2015). Translation of Opioid Pharmacogenomics into Pain Treatment: Commercial Reality versus Regulatory Oversight. Poster session presented at the meeting of PUBLIC HEALTH GENOMICS. KARGER. |
| 2015 | Dom, Z. I. M., Westley, I. S., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2015). Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of mycophenolic acid in renal transplant recipients. Poster session presented at the meeting of Abstracts of the 2015 Golden Helix Symposium - Next Generation Pharmacogenomics, as published in Public Health Genomics. Karger. DOI WoS1 |
| 2014 | Li, Y., Coller, J., Hutchinson, M., Klein, K., Zanger, U., Currow, D., . . . Somogyi, A. (2014). Cyp2B6*6 Allele Alters Ketamine'S Pharmacokinetics In Chronic Pain Patients And Metabolism In Vitro. Poster session presented at the meeting of Drug Metabolism Reviews. Toronto, CANADA: Informa Healthcare. DOI Europe PMC3 |
| 2014 | Loo, C. K., Galvez, V., O'Keefe, E., Glue, P., Somogyi, A., & Shannon-Weickert, C. (2014). Ketamine as an Antidepressant: Investigating New Methods of Administration. Poster session presented at the meeting of BIOLOGICAL PSYCHIATRY. New York, NY: ELSEVIER SCIENCE INC. |
| 2013 | Sallustio, B., Noll, B., Coller, J., & Somogyi, A. (2013). Association Between Intra-Renal P-gp Expression and Cyclosporine Concentrations in Renal Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS. |
| 2013 | Dom, M. Z., Coller, J. K., Somogyi, A. A., & Sallustio, B. C. (2013). Impact of Recipient and Donor Multidrug Resistance Protein 2 Genetic Variability on Mycophenolic Acid Pharmacokinetics Following Kidney Transplantation. Poster session presented at the meeting of THERAPEUTIC DRUG MONITORING. Salt Lake City, UT: LIPPINCOTT WILLIAMS & WILKINS. |
| 2012 | Coller, J., Hutchinson, M., Tuke, J., White, J., & Somogyi, A. (2012). 65. Association between immune genetic markers and opioid dependence. Poster session presented at the meeting of Brain, Behavior, and Immunity. DOI |
| 2011 | Somogyi, A. A., Coller, J. K., Foster, D. B. F., & Li, Y. (2011). ROLE OF CYP2B6 POLYMORPHISM IN THE METABOLISM AND PHARMACOKINETICS OF METHADONE ENANTIOMERS. Poster session presented at the meeting of BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. WILEY-BLACKWELL. WoS1 |
| 2000 | Olver, I., Vadas, M., Lopez, A., Keefe, D., Taylor, A., Brown, M., & To, L. (2000). A phase 1 study of the GM-CSF antagonist E21R. Poster session presented at the meeting of Proceedings of ASCO - Volume 19 2000. USA: American Society of Clinical Oncology. DOI |
| 1986 | MARLIN, G. E., BRAUDE, P. D., WHELAN, A. J., & SOMOGYI, A. A. (1986). BRONCHIAL MUCOSAL CONCENTRATIONS OF A NEW ORAL ANTIPSEUDOMONAL ANTIBIOTIC, ENOXACIN. Poster session presented at the meeting of AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE. ADIS PRESS AUSTRALASIA P/L. |
| Date | Project Title / No. | Investigators | Funding Body | Amount |
|---|---|---|---|---|
| 2016 - 2018 | Ketamine therapy among patients with treatment-resistant depression: a randomised, double-blind placebo-controlled trial. | Loo C, Mitchell P, Glue P, Fitzgerald PB, Glozier N, Lapidus K, Hadzi-Pavlovic D, Somogyi A, Hackett M, Galvez V | NHMRC | $2,069,381 |
| 2015 - 2017 | Personalised Medicines for Aboriginal Peoples | Somogyi AA, Jamieson L, Dettwiller P | NHMRC | $1,066,571 |
| 2014 - 2017 | Improving the treatment of breathlessness- a phase III randomised, controlled trial of sustained released morphine for the symptomatic treatment of of chronic refractory breathlessness. | Currow D, Abernethy A, McDonald C, Miners J, Johnson M, Quinn S, Kirkpatrick C, Somogyi A, Denehy L, McCaffery N | NHMRC | $860,807 |
| 2014- 2015 | Predictors of persistent postsurgical pain following total knee joint arthroplasty. | MT Kluger, PJ McNair, AA Somogyi, GN Lewis | Australian and New Zealand College of Anaesthetists | $36000 |
| 2013 - 2015 | Evaluating the effect of morphine on obstructive sleep apnoea. | Wang D, Eckert D, Somogyi A, Grunstein R, Wong K | NHMRC | $515,779 |
| 2001 - 2004 | Pain and Analgesic Response in Opiate Dependence | W Ling, K Miotto, J White, A Somogyi, F Bochner | National Institutes of Health | $1, 591, 603 |
| 2009 - 2011 | The role of OCT-1 Activity enhancers in improving the response of patients with low OCT-1 activity to imatinib. | White D, Hughes T, Somogyi A, Melo J | Leukemia and Lymphoma Society Translational Research Grant | $600, 000 |
| 2011 - 2012 | Signalling pathway pharmacogenomics and opioid response: beyond the mu opioid receptor. | Somogyi AA (CIA) | NHMRC | $240, 000 |
| 1983 -present | 24 grants | Multiple researchers | NHRMC | $13, 000, 000 |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2025 | Principal Supervisor | Pharmacokinetics and pharmacogenetic studies in perioperative medicine | Doctor of Philosophy | Doctorate | Full Time | Mr Matthew Kah Lup Ng |
| 2025 | Principal Supervisor | Pharmacokinetics and pharmacogenetic studies in perioperative medicine | Doctor of Philosophy | Doctorate | Full Time | Mr Matthew Kah Lup Ng |
| 2021 | Co-Supervisor | Investigation of Genetic Polymorphisms That Could Interfere With Drug Metabolism of Omeprazole in Horses | Doctor of Philosophy | Doctorate | Part Time | Dr Gustavo Ferlini Agne |
| 2021 | Co-Supervisor | Investigation of Genetic Polymorphisms That Could Interfere With Drug Metabolism of Omeprazole in Horses | Doctor of Philosophy | Doctorate | Part Time | Dr Gustavo Ferlini Agne |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2019 - 2023 | Principal Supervisor | Development and application of methods for pharmacokinetics (PK) analysis in PNG HIV/AIDS patients | Doctor of Philosophy | Doctorate | Full Time | Ms Natalia Bordin Andriguetti |
| 2015 - 2019 | Principal Supervisor | Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes | Doctor of Philosophy | Doctorate | Full Time | Ms Rong Hu |
| 2014 - 2015 | Principal Supervisor | Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib | Master of Philosophy (Medical Science) | Master | Full Time | Mr Muhammad Suleman Khan |
| 2011 - 2017 | Co-Supervisor | Mycophenolic Acid Pharmacokinetics and Clinical Outcomes in Renal Transplantation: Effect of ABCC2 Haplotype Analysis and Distribution into Lymphocytes and Kidney | Doctor of Philosophy | Doctorate | Full Time | Mr Zaipul Izwan Md Dom |
| 2011 - 2017 | Co-Supervisor | Neuroimmunopharmacology of Opioids | Doctor of Philosophy | Doctorate | Full Time | Dr Jacob Henry Lloyd Thomas |
| 2010 - 2014 | Principal Supervisor | Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine | Doctor of Philosophy | Doctorate | Full Time | Mr Yibai Li |
| 2009 - 2011 | Principal Supervisor | CNS Immune Signalling and Drug Addiction: Role of Interleukin-1 Beta | Doctor of Philosophy | Doctorate | Full Time | Mr Liang Liu |
| 2008 - 2011 | Principal Supervisor | The Neuroimmunopharmacology of Alcohol | Doctor of Philosophy | Doctorate | Full Time | Miss Yue Wu |
| 2007 - 2011 | Co-Supervisor | Two methods of biomarker discovery: applications in neuropathic pain and pharmacotherapy | Doctor of Philosophy | Doctorate | Full Time | Mr Peter Grace |
| 2007 - 2013 | Co-Supervisor | The Stereoselective Pharmacodynamics of the Enantiomers of Perherhexiline | Doctor of Philosophy | Doctorate | Part Time | Dr Johnny Licari |
| 2006 - 2013 | Principal Supervisor | The Effect of Opioids on Emotional Reactivity | Doctor of Philosophy | Doctorate | Full Time | Mr Steven Savvas |
| 2005 - 2010 | Principal Supervisor | Pharmacogenomics of ABCB1 in Maintenance Pharmacotherapies for Opioid Dependence | Doctor of Philosophy | Doctorate | Full Time | Dr Daniel Barratt |
| 2003 - 2007 | Co-Supervisor | Evaluation and Treatment of Opioid-Induced Hyperalgesia | Doctor of Philosophy | Doctorate | Full Time | Mr Justin Hay |
| 2003 - 2008 | Co-Supervisor | The Stereoselective Pharmacokinetics of the Enantiomers of Perhexiline in Poor and Extensive Metabolisers of the Cytochrome P450 2D6 | Doctor of Philosophy | Doctorate | Full Time | Mr Benjamin Davies |
| 2002 - 2007 | Co-Supervisor | Clinical Pharmacology of Methadone Induction | Doctor of Philosophy | Doctorate | Part Time | Ms Erin Morton |
| 2001 - 2005 | Co-Supervisor | ENHANCING THE USE OF OPIOIDS IN PAIN MANAGEMENT: ANTINOCICEPTIVE POTENTIATION WITH OPIOID AGONIST/ANTAGONIST COMBINATIONS | Doctor of Philosophy | Doctorate | Full Time | Dr Sophie La Vincente |
| 2001 - 2013 | Principal Supervisor | Opioid Maintained Subjects and the Effects of High Dose Morphine and Adjuvant Analgesics | Doctor of Philosophy | Doctorate | Full Time | Mr Peter-Allan Athanasos |
| 2000 - 2004 | Co-Supervisor | A comparison of methadone and slow-release oral morphine as maintenance pharmacotherapies for opioid dependence | Doctor of Philosophy | Doctorate | Full Time | Mr Timothy Mitchell |
| 2000 - 2004 | Principal Supervisor | Opioids and Immune Function: The Role of Non-Classical Opioid Receptors and the Association with Pain Perception | Doctor of Philosophy | Doctorate | Full Time | Prof Mark R. Hutchinson |
| 1998 - 2002 | Co-Supervisor | ACUTE PAIN MANAGEMENT IN METHADONE MAINTENANCE TREATMENT | Doctor of Philosophy | Doctorate | Full Time | Mr Mark Doverty |
| 1997 - 2006 | Co-Supervisor | An Examination of the Pharmacodynamics and Pharmacokinetics of Levo-alpha-acetylmethadol (LAAM), compared to Methadone, in Opioid Maintenance Patients | Doctor of Philosophy | Doctorate | Full Time | Mr David Newcombe |
| 1997 - 2010 | Principal Supervisor | The in vitro and in vivo Formation and Potency of 6 -Naltrexol, the Major Human Metabolite of Naltrexone | Doctor of Philosophy | Doctorate | Full Time | Ms Susan Porter |
| Date | Role | Board name | Institution name | Country |
|---|---|---|---|---|
| 1993 - 2000 | Member | Faculty of Science Board | University of Adelaide | Australia |
| Date | Role | Committee | Institution | Country |
|---|---|---|---|---|
| 2015 - ongoing | Member | Pharmacogenomics Executive Committee | International Association of Therapeutic Drug Monitoring and Clinical Toxicology | Australia |
| 2015 - ongoing | Chair | Therapeutics Goods Committee | Therapeutics Goods Administration, Department of Health, Canberra | Australia |
| 2014 - ongoing | Member | Pharmacogenetics Executive Committee | International Union of Basic and Clinical Pharamacology | - |
| 2012 - ongoing | Member | Excellence in Research for Australia Research Evaluation Committee | Australian Research Council | Australia |
| 2010 - ongoing | Member | Excellence in Research for Australia Research Evalutation Committee | Australian Research Council | Australia |
| 2010 - 2014 | Member | Research Executive Committee | University of Adelaide | Australia |
| 2004 - ongoing | Member | Research Committee, Faculty of Pain Medicine | Australian and New Zealand College of Anaesthetists | Australia |
| 2002 - 2016 | Member | Advisory Committee on Nonprescription Medicine (ACNM) | Department of Health (Canberra) | Australia |
| 2001 - 2005 | Member | Higher Degrees Committee | University of Adelaide | Australia |
| 2000 - 2005 | Member | Grants and Personnel Subcomittee of Research Comittee | University of Adelaide | Australia |
| 1999 - 2005 | Member | Research Committee | University of Adelaide | Australia |
| 1998 - 1998 | Member | Organising Committee | International Meeting of the International Society for the Study of Xenobiotics | United States |
| 1998 - 2000 | Member | Hospital Scientists Assessment Committee | The Queen Elizabeth Hospital | Australia |
| 1995 - 1995 | Chair | Local Organising Comittee | Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists | - |
| 1994 - 2011 | Member | Research Review Committee | Royal Adelaide Hospital | Australia |
| 1994 - 1998 | Member | Division of Health Sciences Information Technology Committee | University of Adelaide | Australia |
| 1994 - ongoing | Member | Research Ethics Committee | Royal Adelaide Hospital | - |
| 1990 - 1996 | Member | Ethics of Human Research Committee | The Queen Elizabeth Hospital | Australia |
| 1987 - 1987 | Member | Organising Committee | International Symposium on Microsomes and Drug Oxidations | Australia |
| Date | Role | Membership | Country |
|---|---|---|---|
| 2013 - ongoing | Member | Member NHMRC Grant Review Panel – 3B | Australia |
| 2010 - ongoing | Member | Member NHMRC Grant Review Panel – 3A | Australia |
| 2006 - 2009 | Member | Member of NHMRC Grant Review Panel –Pharmacology | Australia |
| 2005 - 2007 | President | The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists | Australia |
| 2000 - 2002 | Member | NHMRC Discipline Panel | Australia |
| 1997 - 2000 | Secretary | The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists | Australia |
| 1995 - 1996 | Council | The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists | Australia |
| Date | Role | Editorial Board Name | Institution | Country |
|---|---|---|---|---|
| 2010 - 2014 | Editor | European Journal of Clinical Pharmacology | - | - |
| 2010 - ongoing | Member | Pharmacogenomics and Personalized Medicine | - | - |
| 2007 - ongoing | Member | Journal of Opioid Management: a medical journal of proper and adequate use | - | - |
| 2007 - 2015 | Editor | British Journal of Clinical Pharmacology | - | Australia |
| 2002 - ongoing | Member | Pharmacogenetics and Genomics | - | - |
| 1998 - ongoing | Member | Australian Medicines Handbook | - | Australia |
Connect With Me
External Profiles
